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Haemopoietic Stem Cell Transplant (HSCT) is used as a treatment for a 
number of conditions, particularly leukaemias. Following conditioning and 
HSCT, there is a ‘resetting’ of the immune system, which reconstitutes over a 
number of months. Graft-versus-Host Disease (GvHD) is a life-threatening 
complication of HSCT that can be associated with sight-threatening dry eye 
disease. In GvHD, transplanted immune cells mount an immune response 
against the host. 
This thesis investigated how the immune cells of the conjunctiva reconstitute 
following HSCT. A non-invasive technique, ocular surface impression cytology 
(OSIC), was used to demonstrate that, whilst there was no apparent depletion 
of innate immune cells in the conjunctiva, there was a marked reduction in the 
lymphocytes, which gradually reconstitute, returning to normal levels at the 6 
month time point.  
Secondly OSIC was used to profile the conjunctival leukocyte population in a 
cohort of patients post-HSCT with and without eye disease and compared to 
the leukocyte conjunctival leukocytes in both healthy volunteers and patients 
with another form of aqueous deficient dry eye disease, primary Sjogren’s 
Syndrome(pSS). In patients with dry eye disease following HSCT, the 
conjunctiva contained increased numbers of CD8+ lymphocytes, macrophages 
and neutrophils when compared to healthy volunteers and increased numbers 
of macrophages when compared to patients with pSS. These data demonstrate 
that in dry eye disease post-HSCT, there is active inflammation, and this is 
distinct to the inflammation found in pSS supporting the hypothesis that there is 
a Graft-versus-Host reaction in the conjunctiva that is distinct to that caused by 
aqueous deficiency dry eye disease alone. 
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Chapter 1 Introduction 
Haemopoietic Stem Cell Transplant 
Ernst Neumann first described the haemopoietic stem cell (HSC) at the turn of 
the last century.10 HSCs are multipotent, self-renewing cells that replicate to 
form the variety of cells found in the blood, including erythrocytes, leukocytes 
and platelets.  HSCs are predominantly found in the bone marrow, most notably 
in the long bones and the pelvis, where they form 0.01% of the total cell mass; 
a very small number of HSCs can also be found in the peripheral blood.  
In the early part of the 20th Century, leukaemia was essentially an untreatable 
disease. The advent of chemotherapy agents in the post-war period, in 
particular antimetabolites, offered the first opportunity to treat leukaemia11 but 
such treatment was limited both by the toxicity of the agents used and the 
potential for drug resistant disease.  
In 1957 Thomas et al transplanted bone marrow intravenously12, although this 
graft failed to permanently engraft, transient engraftment occurred in one 
patient, proving the concept and in 1959 Thomas et al13 successfully 
transplanted bone marrow between identical twins, but successful allogenic 
transplantation remained elusive. In 1958, six Yugoslavian physicists were 
exposed to a lethal dose of radiation following an accident at the Vinca Nuclear 
Center in Belgrade. Since HSC turnover rapidly, these cells are at a particularly 
high risk from radiation-induced damage and all six patients rapidly deteriorated 
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with one succumbing to the disease. The remaining 5 patients received bone 
marrow infusions, but engraftment failed in all cases. In 1958 Thomas et al14 
published successful homograft in dogs; unfortunately animals in whom 
engraftment successfully occurred later succumbed to a constellation of 
complications such failure to thrive, diarrhoea, hepatomegaly and 
splenomegaly. With the discovery in the 1960’s of the structure and function of 
the MHC complex successful HSCT became a real possibility, and 
consequently, in 1968, the first successful HSCT was performed by Good et 
al.15 
The European Group for Blood and Marrow Transplantation (EBMT) reported 
that in 2015, a record number of HSCT’s were performed, 42,171 transplants 
were performed in 655 European centres, of which 21,596 were allogenic 
transplants16, an increase of almost 300% on 2005 numbers. The most 
common indications for HSCT are the leukaemias and lymphoproliferative 
disorders, however 1985 allogenic HSCTs were performed for benign disease, 
the most common benign indication being severe aplastic anaemia. More 
recently there has been increased interest in using myeloablation and 
autologous HSCT to treat autoimmune disease, including Systemic Lupus 
Erythromatosus, 17,  Multiple Sclerosis.18 and systemic sclerosis.19  When used 
to treat these diseases, the patient’s bone marrow is terminally suppressed, so 
much so that the patient is unable to produce any blood cells; this 
myeloablation depletes the patient’s autoreactive immunological compartment. 
The immune system is then ‘reset’ with autologous stem cell transplant; with 
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naïve lymphocytes produced from the bone marrow and thymic reactivation 
producing naïve T-cells and T-regulatory cells (T-reg).20  
Reconstitution 
Following myeloablation, the bone marrow HSC population is depleted and so 
the bone marrow is unable to produce any blood cell components. Following 
HSCT, engraftment of transplanted haemopoietic stem cells allows the bone 
marrow to produce blood cells. In the first few days following transplant, the 
levels of all cellular components of blood plummet, requiring red cell transfusion 
and measures to prevent infections. 21 Leukocyte numbers subsequently rise 
reconstituting both leukocyte and erythrocyte populations. Reconstitution is a 
dynamic process with interplay between numerous factors, including surviving 
host leukocytes, donor leukocytes from the graft, new leukocytes originating 
from engrafted haemopoietic stem cells, treatment given as part of the 
transplant protocol, and the environment, including latent viruses. Different cell 
populations reconstitute at different time points; this is shown in Figure 1.  
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Figure 1 From Bosch et al21, depicting the different rates of reconstitution of different 
blood cellular components following myeloablation and transplant. Innate cells 
reconstitute early on, reaching normal levels within week or months, whereas 
lymphocytes take longer, reaching normal level months or years following HSCT.  
Innate immune cells derived from the transplanted marrow reconstitute in the 
early post-transplant period, with levels in the blood reaching normal in the first 
few weeks after HSCT. Neutrophils reconstitute first, with normal levels as soon 
as 11-14 days after transplant. 22  Monocytes and NK cells reconstitute to 
normal levels by day 30.23 In contrast dendritic cell number fall in less than 24 
hours following myeloablation and their numbers recover much more slowly, 
with levels approaching normal levels up to one year following HSCT.24 
Interestingly, in the skin, dendritic cell levels have been shown to return to a 
normal level by day 112. 25 
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Lymphocytes, in general, take longer to reconstitute and the process of 
reconstitution is different for different subsets of lymphocytes. B-cell 
reconstitution follows a path remarkable similar to the natural maturation and 
evolution of B-cells. B-cells levels drop rapidly following myeloablation26 with 
levels taking over a year to reach normal. Reconstituted B-cells are mainly of 
donor origin27, and naïve B-cells are found in the blood first, with memory B-
cells appearing later. 23, Despite host B-cells being barely detectable in the 
blood27 following myeloablation, B-cells in the lymph nodes prove themselves to 
be highly resistant as host immunoglobulins are detectable in the serum up to 
two years following HSCT. 28 In stark contrast, T-cell reconstitution follows a 
distinctly different path to their normal maturation. T-cell reconstitution follows a 
biphasic pattern. In addition to haemopoietic cells, HSCT also transplants 
mature T -cells and through peripheral expansion, effector memory T-cells 
predominate in the early stages of reconstitution forming the first wave of T-
cells. 29  In response to low lymphocyte numbers, naïve T-cells mature in the 
thymus, forming the second wave of T-cell expansion.30 .This process is slow, 
and naïve T-cells can take decades to reach normal levels31, in part due to poor 
thymic function impairing T-cell maturation, especially in the elderly. 32 CD8+ 
cells reconstitute significantly earlier than CD4+ cells31 and as a result the 
CD4:CD8 ratio changes switching in favour of CD8+cells.33  This is thought to 
be due to herpetic viruses driving effector memory expansion with VZV34,35 and 
CMV 36-38 implicated. Nevertheless, reconstitution of CD4+ cells confers 
increased survival and disease-free remission. 39 On reconstitution the balance 
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of regulatory to effector T-cells is skewed towards effector cells, which is 
clinically relevant as higher levels of effector T-cells and lower levels of T-reg 
cells confer an increased risk of GvHD.40 Host derived T-regs have been shown 
to be reconstitute early on, reaching normal levels as early as 4 weeks in animal 
models. 41 
Tissue Reconstitution 
Due to the difficulty in obtaining tissue samples, less is known about 
reconstitution of tissue resident leukocytes in humans. It has been shown that 
infused donor lymphocytes can enter tissues at an incredibly rapid rate, up to 
10 billion cells in half an hour. 27 In the intestine, there are clinical implications of 
leukocyte trafficking to the gut; early neutrophil translocation is implicated in the 
initiation of acute GvHD42 and blockade of T-cell entry into the intestine may 
help to prevent acute GvHD.43 
Graft-versus-Host Disease 
Mechanism of GvHD 
Early animal models of stem cell transplantation were limited by a constellation 
of disease consisting of diarrhoea, dermatitis, splenomegaly and wasting, the 
syndrome becoming known as term ‘secondary disease’44 or ‘runt’ disease. 45 It 
was noted that the animals that were most likely to succumb, were those in 
whom successful engraftment had taken place. It later became apparent that 
secondary disease was due to the transplantation of fully functional mature 
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lymphocytes attacking the host, and the phenomenon became known a Graft-
versus-Host Disease (GvHD). 
In the late 1950’s, Billingham described three pre-requisites for GvHD to 
occur.46 
1. [The transplant] “must contain mature immunologically competent cells” 
2. “The host must possess important transplantation antigens” 
(histocompatibility genes) which are lacking in the graft 
3. “The host must itself be incapable of reacting against the graft” 
This logic explains why a corneal transplant is highly unlikely to cause GvHD, 
since although the majority of corneal transplants are not MHC matched, the 
transplant does not contain a significant number of immunocompetent cells, and 
the host’s immune system is intact. Conversely HSCT is much more likely to 
cause GvHD, since the transplant contains not only the desired haemopoietic 
stem cells but mature immunocompetent cells; there are minor 
histocompatibility mismatches even in a fully MHC matched transplant and the 
host’s own immune mechanisms have been compromised by the preceding 
disease treatment or conditioning. 
Early use of therapy targeted against T-cells in dogs47 highlighted the role of T 
cells in the pathogenesis of GvHD. T-cell suppression with methotrexate and 
calcineurin inhibitors became regularly used to reduce the risk of GvHD and it 
was also shown that removing or depleting the ‘immunocompetent’ T-cells  from 
the donor infusion was effective at reducing the formation of GvHD.48 The risk 
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of developing chronic GvHD is also significantly increased, if there has been 
previous acute GvHD.49-55 
Graft Versus Leukaemia Effect 
It also became apparent that the presence of GvHD, whilst causing significant 
morbidity to patients, was reducing the risk of leukaemia relapse. GvHD 
conferred a reduction in leukaemia relapse rate, 56 and overall survival57; and 
strategies to reduce GvHD increased the risk of relapse58. The use of Donor 
Lymphocyte Infusions (DLI) to induce disease remission59 provided further 
evidence of the ‘anti-leukaemic’ effect of lymphocyte infusion, now known as the 
Graft-versus-Leukaemia effect (GVL).  
Classification of GvHD 
 Classically GvHD has been classified by time point, with manifestations 
occurring before 100 days being classified as acute Graft-versus-Host Disease 
(aGvHD), and those after 100 days as chronic Graft-versus-Host Disease 
(cGvHD). Modern therapeutic regimes and treatment have somewhat blurred 
this margin, in particular the use of reduced intensity conditioning, ‘top up’ 
HSCT/DLI and modern immunosuppression. It is entirely possible with reduced 
intensity conditioning for aGvHD to present ‘late’ or for both acute and chronic 
GvHD manifestations to occur simultaneously following DLI or withdrawal of 
systemic immunosuppression. A consensus document was therefore published 
by the National Institute for Health in 20052 which recommended that GvHD 
should not only be classified as acute or chronic based on the timing of the 
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clinical features, but also on the clinical pattern of disease. Furthermore, a 
detailed scoring system for cGvHD was proposed which splits the clinical 
features of cGvHD into organ systems and then assigns a score (from 0-3)  
according to the severity of involvement. A score of 0 denotes no involvement, 1 
denotes no clinical significant functional impairment, 2 denotes clinically 
significant impairment and 3 denotes major disability. Depending on which 
organs are affected, the number of organs affected, and how severely they are 
affected; the severity of cGvHD is then classified as ‘Mild’, ‘Moderate’ or 
‘Severe’. This classification is summarised in Table 1 
In 2015, after this study had finished, these criteria were modified and updated. 
60 The general principle and structure is unchanged, but there are minor 
Mild GvHD • 1 or 2 organs involved  
• No Lung Involvement 
• Maximum severity score of 1 in any 
site 
Moderate GvHD • At least 1 with severity score of 2 but 
not >2 
-or- 
• 3 or more sites with severity score of 
1 
-or- 
• Lung score of 1 
Severe GvHD • Severity score of 3 in any organ site 
-or 
• Lung score of 2 or more 
Table 1 NIH Classification of chronic GvHD from Filipovich et al.2 The severity of 
GvHD depends on both the number of organs involved, and the severity of organ 
involvement. 
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alterations and clarifications to the system. As this was published after our study 
finished, the 2005 NIH classification are used throughout. 
Classification of Ocular GvHD 
NIH 
The NIH classification of GvHD describes the severity of each system that can 
be involved in cGvHD, including the eyes. Ocular disease is graded as mild, 
moderate or severe (Table 2).  
The 2005 NIH classification uses unanaesthetised Schirmer’s test. Schirmer’s 
test described in the DEWS report61 and is a basic measure of tear production: 
a strip of filter paper is inserted into the lower eyelid for five minutes. The length 
of the strip that is wet by the tears is then measured. The less the length that is 
wet, the fewer tears and the drier the eye. The NIH classification defines new 
onset ocular keratoconjunctivitis sicca (KCS) documented by a low 
unanaesthetised Schirmer test values with a mean value of both eyes <5 mm at 
5 minutes; or mean values of 6 to 10 mm accompanied by evidence of dry eye 
disease on slit-lamp examination. Using the NIH classification new onset KCS 
and symptoms of cGvHD in one other system is enough to diagnose cGvHD. 
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Mild Ocular GvHD (Score 1) Mild dry eye symptoms not affecting 
ADL (requiring eyedrops <3xperday) 
OR 
asymptomatic signs of 
keratoconjunctivitis sicca 
Moderate Ocular GvHD (Score 2) Moderate dry eye symptoms 
partially affecting ADL (requiring 
drops>3xperday or punctal plugs), 
WITHOUT vision impairment 
Severe Ocular GvHD (Score 3) Severe dry eye symptoms 
significantly affecting ADL (special 
eyewear to relieve pain)  
OR 
unable to work because of ocular 
symptoms  
OR 
loss of vision caused by 
keratoconjunctivitis sicca 
Table 2 NIH classification of ocular GvHD from Filipovitch et al2. The severity of ocular 
disease is classified according to both symptoms and signs of ocular disease. 
Symptoms are described according to how the patient’s activities of daily life (ADL) are 
affected and how often the patient needs to use treatment for their eye disease. Signs 
used are unspecified ‘signs of keratoconjunctivitis sicca’ or vision. 
This system is designed to be used both by ophthalmologists and non-
ophthalmologists; and can be assessed by transplant specialists in the 
transplant clinic as well as in the ophthalmology clinic. As such, specialist 
investigations and examination techniques that are usually applied to dry eye 
disease, are not included in the classification. This has led to criticism of the 
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system as it is difficult to compare the NIH scale with other dry eye disease 
states, and there is a lack of granularity that might be required for more detailed 
purposes, such as research. Nevertheless, the classification has stood up well 
to scrutiny: a large multicentre study by Inamoto et al62 compared the five 
candidate scales including NIH scale with patient and clinician reported 
changes in symptoms and found the NIH eye score showed fair correlation with 
both patient and clinician reported assessment. Furthermore, the NIH scale, 
which was not originally designed to measure serial changes, was found to be 
the most sensitive to patient reported symptom scales. Nevertheless, even 
given these findings, the authors recommend that for “clinical trials specifically 
targeting ocular symptoms, other detailed and objective ophthalmology criteria 
might be necessary to document ocular chronic GvHD activity”. 
Tatematsu et al63 compared the NIH score with two other scores, including the 
Japanese Dry Eye Score and the Dry Eye Workshop (DEWS) scale64, also 
finding a good correlation between the three scores, although they found a 
number of discrepancies, and express concern that patients with ocular GvHD 
as defined by the NIH criteria may have low DEWS and/or Japanese Dry Eye 
Scale score, leading the possibility of overtreatment and the potential 
complications this might entail. Furthermore, there are concerns about the use 
of Schirmer’s score in the NIH definition of new onset KCS. In the above study 
by Inamoto et al62, whilst there was a correlation between patient and clinician 
scores and the NIH classification, there was not a correlation with Schirmer’s. In 
a prospective study of 53 patients post-HSCT, found a false positive 19.4% and 
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a false negative of 36.4% when compared with a global assessment of dry eye 
disease using tear film break up time or a positive cotton thread test or ocular 
surface abnormality detected on slit lamp examination with fluorescein or rose 
bengal. 
As mentioned above, in 2015 the NIH system was modified60 and the ocular 
component was simplified, removing the Schirmer’s criteria. 
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International Chronic Ocular Graft-vs-Host-Disease (GvHD) Consensus Group: 
Proposed Diagnostic Criteria 
In light of these criticisms, an International Consensus group was formed and a 
new classification system was devised and published in 2013. 6 This system 
combines four main factors, unanaesthetised Schirmer’s, corneal fluorescein 
staining (CFS), OSDI patient reported symptom scale and the presence and 
severity of conjunctival hyperaemia. Image based grading scales are provided 
for conjunctival injection (Figure 2) and CFS (Figure 3). Comparison with these 
sign of chronic GVHD without being substantiated by involvement
in other organ systems as originally recommended by the NIH
working committee.
Proposed diagnostic criteria and severity of grading system. A
collaborative, prospective-multicenter study from the USA, the
Netherlands, and Japan on ocular GVHD has been proposed.
Based on discussion and consensus at the 1st Chronic Ocular
GVHD meeting, the parameters for diagnosis include 1) Ocular
Surface Disease Index (OSDI)43,44, 2) Schirmer’s test score without
anesthesia45, 3) Corneal fluorescein staining (Figure 3)45,46, and 4)
conjunctival injectio (Figure 4)47. Ocular GVHD classification
will be based on the baseline examination as threshold scores for
grading. The proposed grading system is shown in Tables 1 and 2.
Severity scores 0, 1, 2, and 3 will be assigned to OSDI, corneal
fluoresecein staining, and Schirmer’s score44–46. Conjunctival injec-
tion will be scored 0, 1, and 2 (Table 1)47. The corneal fluorescein
staining score ranged from 0 to 3 points (Grade 0 5 no staining,
Grade 1 5 minimal staining, Grade 2 5 mild/moderate staining,
Grade 3 5 severe staining) (Figure 3)46. The conjunctival
hyperemia score of the conjunctiva ranged from 0 to 2 points
(Grade 0 5 none, Grade 1 5 mild/moderate, Grade 2 5 severe)
(Figure 4)47. Any score above 1 points is regarded as abnormal.
Disease severity will be graded as none, mild/moderate and severe
based on an aggregate of scores for each parameter (Table 1). Based
on the presence or absence of systemic GVHD and the aggregate
scores assessed, a diagnosis of ocular GVHD will be made (Table 2).
In the presence of systemic GVHD, score 0–3 indicates absence of
Figure 2 | Histological findings of lacrimal gland ducts and clinical
findings of orifices of meibomian gland and Zeiss gland on eye lid
margin. (A) Typical histological findings of lacrimal gland focusing on
medium sized duct and from a patient of chronic GVHD for diagnostic
purpose and clinical findings around ductal orfices of meibomian and
Zeiss gland in the lid margin of a 21-year-old male patient with chronic
GVHD. CD45 immunostaining of inflammatory cells in lacrimal gland
from a chronic GVHD patient. An abundant CD451 inflammatory cell
infiltration at periductal areas of lacrimal gland chronic GVHD. A 39-year-
old female patient at 2 months after onset of cGVHD related dry eye.
Original magnification: X630. (B) Note total obstruction of meibomian
gland and Zeis gland orifices and severely fibrotic tarsal conjunctiva. Upper
eye lid, right eye. A 21-year-old male suffering from chronic GVHD.
Figure 3 | Slitlamp micrograph of grading scale for corneal fluorescein
staining. Grading scale of corneal fluorescein staining score ranged from 0
to 3 points (Grade 0 5 no staining, Grade 1 5 minimal staining, Grade 2 5
mild/moderate staining, Grade 3 5 severe staining).
Figure 4 | Slit lamp micrograph of grading scale for conjunctival
injection. Grading scale of conjunctival injection score ranged from 0 to 2
points (Grade 0 5 none, Grade 1 5 mild/moderate injection, Grade 2 5
severe injection).
www.nature.com/scientificreports
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Figure 2 Grading scale for 
conjunctival injection from 
the International Ocular 
GVHD Consensus Group 
Proposed Diagnostic Criteria 
of Chronic GVHD from 
Ogawa et al6. 
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images allows the examiner to assign a severity score for both CFS and 
conjunctival inflammation. These scores are then combined with the Schirmer’s 





















0 > 15 0 <13 None 
1 11-15 <2 13-22 Mild/Moderate 
2 6-10 2-3 23-32 Severe 
3 ≤5 ≥4 ≥33  
Table 3 International Consensus ocular GvHD proposed diagnostic criteria, numerical 
scoring system for each clinical component from Ogawa et al6 . Severity score/points 
from the first are ascribed for each of the four clinical indices assessed and these four 










Systemic GvHD (-) 0-5 6-7 ≥8 
Systemic GvHD (+) 0-3 4-5 ≥6 
Table 4 International Consensus proposed diagnostic criteria for ocular GvHD from 
Ogawa et al6. The composite score from Table 3 is used in this table to derive the 
diagnosis. If the patient has evidence of systemic GvHD, i.e. GvHD in another organ, then 
the composite score from ocular examination required to make a diagnosis of ocular 
GvHD is reduce, i.e. the threshold for making a diagnosis of ocular GvHD is less in 
patients with systemic GvHD. 
The patient’s ocular disease is then categorised into ‘None’, ‘Probable [ocular] 
GvHD’ and ‘Definite [ocular] GvHD’ depending on the composite score and the 
presence or absence of systemic GvHD (Table 4). A study by Rapoport et al65 
retrospectively compared the consensus criteria with a composite ‘best clinical 
practise’ score on cross-sectional basis, and found that a slight agreement 
between the best clinical practise score and consensus criteria (kappa 0.187) 
with the correlation especially useful for patients with more severe disease, 
although they conclude that further validation through larger studies might be 
required. 
Skin GvHD 
Dermatological manifestations of GvHD are common and present in with 
diverse clinical features. Cutaneous GvHD is the most common form of GvHD, 
affecting more than 80% of patients with acute GvHD66 
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Acute Cutaneous GHVD 
Cutaneous GvHD is usually the earliest clinical manifestation of GvHD, often 
presenting as an acute follicular reaction centred around the hair follicles67 , 
which may mimic a bacterial or fungal infection. The subsequent clinical 
manifestations are defined using the International Bone Marrow Transplantation 
Registry (IBMTR) grading system68 shown in Table 5. 
 
Histological features of acute cutaneous GvHD following T-Cell depleted HSCT 
were described by Fischer et al69. In the epidermis there is diffuse epidermal 
hyperplasia (acanthosis) and basal keratinocyte vacuolation. In the dermal 
layer, there is dermal lymphocyte exocytosis and satellitosis, accompanied by 
an infiltrate of neutrophils, plasma cells, macrophages70 and eosinophils. 
Grade Clinical Manifestation 
Grade I Maculopapular Rash <25% body surface area (BSA) 
Grade II Maculopapular Rash 25%-50% body surface area (BSA) 
Grade III Maculopapular Rash >50% body surface area (BSA) 
Grade IV Generalised erythroderma plus bullae +/- generalized 
epidermal necrosis 
Table 5 International Bone Marrow Transplant Acute Cutaneous GvHD Grading Scheme 
from Filipovich et al2. The severity of acute cutaneous GVHD is dependent on the Body 
Surface Area (BSA) affected, with the most severe disease characterised by bullous or 
necrotic skin disease.  
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Bruggen et al71 found an increased number of CD8+ lymphocytes in skin 
biopsies of patients with acute GvHD. Throughout both the dermis and 
epidermis there is keratinocyte necrosis. 
 Chronic cutaneous GvHD can take a number of varied clinical manifestations, 
but remains the most common form of cGvHD and is present in almost all 
patients with cGvHD. An NIH consensus document2 stages cutaneous GvHD 
are shown in Table 6. 
The histological features of chronic cutaneous GvHD are well described72,73 with 
the earlier signs being vacuolar degeneration, characterised by apoptosis in the 
basal cell or lower spinosum layers of the epidermis. The histological features of 
cutaneous cGvHD depends on the clinical manifestations and is typically 
categorised into lichen-planus like (or lichenoid) and scleroderma, with 
sclerodermoid being further subdivided into lichen sclerosis, morpheaform and 
eosinophilic faciitis. 74 
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Table 6 NIH Consensus Grading Scheme for Cutaneous GvHD from Filipovich et al2. 
Chronic cutaneous GVHD is can manifest in a number of different clinical entities. Those 
are described and the severity determines by the Body Surface Areas (BSA) involved, 
with sclerotic skin disease classified as more severe. 
 Nevertheless, there are common histological features found in cutaneous 
cGvHD and they are similar to those found in cutaneous aGvHD. There is an 
interface dermatitis with basal keratinocyte vacuolation at tips of rete ridges and 
follicular epithelium. In the epidermis, there is mild intercellular oedema and 
exocytosis of individual mononuclear cells some juxtaposed to apoptotic 
Clinical 
Features 
o Maculopapular Rash 
o Lichen planus-like features 
o Papulosquamous lesions or icthyosis 
o Hyperpigmentation 
o Hypopigmentation 




o Sclerotic features 
o Pruritis 
o Hair Involvement 
o Nail Involvement 
Score 0 No symptoms 
Score 1 <18% BSA with disease signs but NO sclerotic 
features 
Score 2 29-50% BSA OR involvement with superficial 
sclerotic features “not hidebound” (able to 
pinch) 
Score 3 >50% BSA OR deep sclerotic features 
“hidebound” (unable to pinch) OR impaired 
mobility, ulceration or severe pruritis 
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keratinocytes. Lymphocytic infiltrate is common and may congregate around an 
apoptotic keratinocyte, known a ‘lymphocytic satellitosis’. 73 In chronic lichenoid 
cutaneous cGvHD, CD8+ lymphocytes producing IL-17 predominate, whereas 
in chronic sclerotic cGVHD, there is a mixture of CD4+ and CD8+ 
lymphocytes.71 
Donor CD4+ T-cells are found  in cutaneous lymphoid tissue as early as 2-3 
days following transplantation.75,76 The accompanying systemic cytokine 
release causes local chemokine release, including CXCL9, CXCL10, 
CXCL11.75 Furthermore CXCL10 and its ligand CXCR3 are found in the serum 
of patients with acute skin GvHD. 77  
Oral GvHD 
Oral cGvHD is less common than the cutaneous disease, with clinically 
significant disease affecting up to 24% of patients following HSCT.78 Oral GvHD 
may involve any site in the oral cavity, including the gingiva, hard palate, soft 
palate and tongue. Clinically oral GvHD has four different clinical 
manifestations, either as oral erythema; a lichen-planus like lesion with white 
lacy reticular lines possibly with hyperkeratosis/leukoplakia; a painful ulcerative 
lesion; or as a mucocoele occurring due to fibrous obstruction of minor salivary 
glands.  
Histologically oral cGHVD shares a number of similarities with the cutaneous 
disease, a subepithelial cellular infiltrate and epithelial apoptosis and 
satellitosis. Imanguli et al79 phenotyped these infiltrating cells as predominantly 
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CD3+/CD8+ T-Cells with fewer CD3+/CD8-(CD4) T-Cell, and CD68+ 
macrophage/dendritic cells. Keratinocytes and infiltrating cells in the oral 
mucosa demonstrated the CXCR3 ligand CXCL9 and other migration factors 
including IL-15 and type-1 IFN inducible factors. The infiltrated CD3+/CD8+cells 
were of an effector/memory phenotype (CD45RO+). Infiltrating T-Cells exhibited 
cytotoxic features demonstrating GranzymeB and TIA1 on 
immunohistochemistry. 
Involvement of the minor salivary glands in GvHD causes salivary 
hyposecretion and the sensation of a dry mouth (xerostomia). Xerostomia is 
found in 77% of cases and was almost always associated with dry eye disease. 
80 Histological findings in the salivary glands is characterised by a CD3+ 
lymphocytic infiltrate with preponderance of CD8+ over CD4+ cells in both 
parenchymal and periductal regions. As the disease progresses, there is 
progressive ductal fibrosis and acinar destruction.80 These finding are similar to 
those in the lacrimal gland. 
Intestinal GvHD 
The intestine is the most common organ to be affected in aGvHD. 81 Early 
symptoms such as nausea, vomiting, mild diarrhoea, mild abdominal pain, can 
often be confused with the complications of chemotherapy. At the more severe 
end of the spectrum, the diarrhoea becomes more voluminous, ileus may 
develop and the condition can become life threatening. In cGvHD, intestinal 
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involvement is much less common and often follows on from intestinal aGvHD. 
82Clinically intestinal cGvHD is characterized by diarrhoea and weight loss.  
In the intestine, the inflammatory infiltrate accompanying cGvHD composes 
predominantly of mononuclear cells83 and although not diagnostic, 
lymphocytosis and satellitosis are observed. In a mouse model, the CXCR3 
ligand, CXCL10 have also been shown to be upregulated in the colon. 84 The 
microbiota of the intestine is heavily implicated in the development of intestinal 
GvHD, 85 indeed mice bred in germ-free conditions do not develop GvHD 
suggesting that pathogenesis is driven by dysregulated immune responses to 
commensal microorganisms. 86  
Damage to the intestinal stem cells during conditioning and radiotherapy87 
reduces the barrier function of the small intestine exposing of microbial products 
to the immune system. In response, neutrophil recruitment occurs88 and 
dendritic cell maturation promotes T-cell recruitment.89 Furthermore, dendritic 
cells induce infiltrating T-cells to differentiate to a TH17 phenotype. 90 In a 
mouse model of intestinal GvHD, Zhou et al91  identified a population of central 
memory CD4+ T-cells that expression the β2 integrin CD11c which expressed 
gut homing markers and were able to induce gastrointestinal inflammation on 
adoptive transfer.  
Pulmonary cGvHD 
Clinically pulmonary cGvHD takes the form of Bronchiolitis Obliterans and can 
be diagnosed using lung function tests or radiologically. 2 In a mouse model of 
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pulmonary GvHD, Ohnuma et al92 found a CD4+ infiltrate, and demonstrated 
that CD4+ T-cell production of IL-26 promoted lung fibrosis.  
Ocular GvHD 
The Ocular Surface System 
The ocular surface system (Figure 4) consists of those structures that are 
required to create and maintain the smooth surface of the cornea. 7 It therefore 
composes of the surface epithelia of the cornea and conjunctiva, and the 
structures that support these epithelia, including the lacrimal glands, eyelids, 
Figure 4 The Ocular Surface System taken from Gipson.7 
 a sagittal section illustrating the continuous epithelial surface of the cornea and 
conjunctiva (pink) with associated glandular structures. 
b Frontal view of the ocular surface system, note the systemic involvement of the 
nervous, vascular, immunological and endocrine systems required to maintain a 
healthy ocular surface. 
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eyelashes, Meibomian glands, and smaller glands, such as the accessory 
lacrimal glands, the glands of Moll and Zeiss and finally the nasolacrimal duct to 
drain away waste products of metabolism. 
The cornea is a clear, avascular structure that composes the anterior portion of 
the eye, the main function of which is to allow light into the eye. The conjunctiva 
is a vascular tissue that covers the anterior portion of the eye, excluding the 
cornea, and also lines the inside or posterior aspect of the eyelids. 
The tear film is a complex structure that covers the ocular surface. A functional 
and stable pre-ocular tear film is a prerequisite for clear vision since light 
entering the eye encounters the tear film first, before any other part of the eye. 
The structure of the tear film is complex, and any disturbance by a pathological 
process will have a detrimental effect on the quality of vision. The tear film is 
classically divided into three layers, a superficial lipid layer, a central aqueous  M. E. Stern et al.
FIGURE 1. The Lacrimal Functional Unit. The LFU unifies the complex reflex network connect-
ing the sensory tissues and secretory glands that provide homeostasis on the ocular surface, and
is composed of the ocular surface tissues (cornea, corneal limbus, conjunctiva, conjunctival blood
vessels, and eyelids), the tear secreting machinery (main and accessory lacrimal glands, meibomian
glands, conjunctival goblet, and epithelial cells), and their neural connections. The LFU is tightly
controlled by neural input from the ocular surface tissues. Subconscious stimulation of the corneal
nerve endings triggers afferent impulses through the ophthalmic branch of the trigeminal nerve (V),
which integrate in the central nervous system and the paraspinal sympathetic tract, in turn gener-
ating efferent secretomotor impulses that stimulate secretion of the healthy tear film. Any one of
several sensory stimuli, e.g., pain, microbial/environmental insult, and emotion can stimulate the
tear secreting reflex. Illustration from Beuerman et al. The Lacrimal Functional Unit in Dry Eye and
Ocular Surface Disorders (eds. Pflugfelder SC, Beuerman RW, and Stern ME) (Marchel Dekker, Inc.,
New York, 2004) 11–39.
polyunsaturated essential fatty acids [12], diabetes mellitus [9,10], cigarette smok-
ing [10,13], prolonged video display viewing [11], and low-humidity environments
[14]. Recently, ocular surface wetness was shown to be regulated by corneal TRPM8-
dependent cold thermoreceptors [15], and it is possible that these fibers, along with
other nerve fibers [16], may be reduced with aging, drawing a link between aging,
corneal innervation, and tearing.
CLINICAL MANIFESTATIONS OF DRY EYE
Patients with tear dysfunction typically experience intermittent-to-constant eye irri-
tation, photophobia, and blurred and fluctuating vision. These symptoms are often
exacerbated by prolonged visual effort or a low-humidity environment, such as an air-
plane cabin. Chronic eye irritation may decrease quality of life in afflicted patients. In
fact, the impact of tear dysfunction on quality of life was rated to be equivalent to un-
stable angina using utility assessments [17]. In some cases, the consequences of tear
dysfunction can be devastating and result in functional and occupational disability.
Ocular surface pain and discomfort is a major symptom of chronic dry eye and is
frequently the primary reason patients seek an ophthalmologist. Clinically, there is
disparity in the extent of tearing, corneal innervation, sensitivity, and pain among the
patient population [18–24]. Although not confirmed, ocular surface discomfort may
International Reviews of Immunology
Figure 5 The Lacrimal nctional Unit taken from Bauerman et al. The 
Lacrimal Functional Unit in Dry Eye and Ocular S rface Disorders (M rchel 
Dekker, Inc., New York, 2004) p11-39 
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layer, and a mucous layer that coats the ocular surface epithelium. The ocular 
surface is part of the wider concept of the lacrimal functional unit (Figure 5), 
which consists of those tissues responsible for production and maintenance of 
the tear film. 
Cornea 
Structure and Function of the Cornea 
The cornea is the clear window at the front of the eye. The primary function of 
the cornea is to provide a clear refractive surface for light entering the eye. In 
the mammalian eye, there are two refractive structures that together are 
responsible for focussing the light entering the eye in order to produce a clear 
image on the retina; namely the cornea and the crystalline lens. The total 
optical power of the eye is approximately 60 dioptres; the cornea is responsible 
for two-thirds of this. In order to maintain clarity, the central cornea is an 
avascular structure and hence the tear film is responsible for both providing 
nutrients and eliminating waste products. A healthy tear film is a prerequisite for 
the health of the corneal epithelium. The second function of the cornea is to act 
as a barrier between the external environment and the inside of the globe. 
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The cornea is conventionally described in 5 layers 
1. The Corneal Epithelium 
2. Bowman’s Layer 
3. Corneal stroma 
4. Descemet’s Layer 
5. Corneal Endothelium 
The corneal epithelium is a squamous non-keratinised epithelium approximately 
5-7 cells and 53 microns thick. 93 It is maintained by a population of limbal stem 
cells which migrate centripetally replacing epithelial cells that are naturally shed 
off. The apical surface of the corneal epithelium consists of multiple microvilli, 
which interact with a glycocalyx that forms the mucous layer of the tear film. 
These microvilli are susceptible to disease, including ocular GvHD.94  
Conjunctiva 
Immune microenvironment of the Conjunctiva 
As a mucosal surface, the conjunctiva is an interface between the body and the 
outside world, and as such, there is a constant risk of microbial infection. The 
keratinised epithelium of the epidermis provides significant protection from 
infection; the epithelium of the conjunctiva, however, is not keratinised and so is 
significantly more susceptible to infection. A number of mechanisms therefore 
have evolved, both to protect the ocular surface from infection and to prevent 
an over exuberant immune response. 
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Conjunctival-associated Lymphoid Tissue 
The conjunctiva contains local lymphoid tissue, similar to Mucosal Associated 
Lymphoid tissue found in other organs, e.g. Peyer’s patches in the intestine. 
The conjunctiva-associated lymphoid tissue (CALT) allows local processing of 
antigens and recruitment and activation of lymphoid cells. Steven et al95 
demonstrated in the mouse, that topical stimulation of the conjunctiva produced 
lymphoid aggregates consisting of CD4+ and CD8+ T-cells; B-cells, dendritic 
cells and macrophages. 
Lymphocytes 
Lymphocytes form a major part of the adaptive immune system. As with all 
leukocytes, lymphocytes are produced in the bone marrow from haemopoietic 
stem cells. Lymphocytes then mature in either the Bone Marrow, B-cells or the 
Thymus gland, T-cells. T-lymphocytes can be classified according to their 
function; cytotoxic T-cells destroy tumour cells or host cells that are infected 
with intracellular pathogens and express the surface marker CD8; helper T-cells 
assist other immune cells, for example, encouraging cytotoxic T-cells to destroy 
pathogens, or activating B-cells to produce antibodies. Lymphocytes recognise 
a specific epitope, naïve lymphocytes have not yet encountered their specific 
antigen. Once a naïve lymphocyte encounters it antigen, it undergoes massive 
clonal expansion and differentiation to combat an associated pathogen, the 
lymphocyte is now termed an effector lymphocyte and this change can be 
recognised with a switch in surface markers; in humans, naïve T-cells express 
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the isoform CD45RA, whereas mature T-cells express the isoform CD45RO. 
Once the infection has been dealt with, a number of the lymphocytes that 
recognise this antigen remain both in circulation and resident in tissues, ready 
to respond should the epitope be encountered again. This immunological 
‘memory’ is a defining characteristic of the adaptive immune system. As 
mentioned above, following T-cell depletion and conditioning, there is 
destruction of this memory component of the immune system; with HSCT 
allowing the immune system to be reconstituted. 20  
Memory T-cells are epitope specific T-cells that persist in the circulation, tissues  
and secondary lymphoid organs following resolution of infection. They are 
identified as CD45RO+-96 and can be further subdivided by into CD45RO+ 
CCR7+ Central Memory T-cells (Tcm) and CD45RO+CCR7- Effector Memory T-
cells (TEM). 97 Memory T-cells were originally thought to be limited to only the 
Secondary Lymphoid Organs and the circulation, but have been demonstrated 
in the peripheral tissues where they are more likely to take on a 
cytotoxic/effector role. 98Cytotoxic TEM cells have been demonstrated in the 
healthy human conjunctiva where they may play a role in the recognition of viral 
epitopes.99 A fourth subset of ‘revertant’ T-cells ‘revert’ back and lose CD45RO, 
and express CD45RA. This subset is termed TEMRA cells, they show a low rate 
of cell turnover and exert a cytotoxic effect100 and have been demonstrated on 
the ocular surface.101 
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Intraepithelial lymphocytes (IEL) are found in all mucosal sites, including the 
gastrointestinal tract102, the respiratory tract103 and vaginal tract,104  and play a 
role in the early response to pathogens. Intraepithelial cells can be subdivided 
into two main groups105, Type a are ‘conventional’ T-cells TCR 
αβ+/CD8αβ+.Type b cells comprise of three subsets, TCRαβ/CD8αα+, 
TCRγδ+/CD8αα+ and TCRγδDN (Double Negative). Type a cells are activated 
by antigen presented on MHC I or II through the TCR by professional antigen 
presenting cells.  In contrast Type b IELs respond to antigen presented through 
alternative routes. Their roles are also distinct, Type a cells shuttle from 
systemic circulation into their specific mucosal site, this homing requires the 
integrin αEβ7. Type b cells are implicated in autoimmune disease; gd  cells have 
been shown to have a role in preventing autoimmunity in a number of 
conditions, such as colitis106, rheumatoid arthritis107 and Grave’s disease108. 
In the conjunctival epithelium, the dominant T-cells are a resident population of 
CD8+αβ+ T cells, whose numbers increase with age109, express mucosal 
homing signals αEβ7 and are cytotoxic.99 These CD8+ T-cells are predominantly 
effector memory cells, although there are detectable numbers of naïve cells. 
Bose et al101  found in healthy human conjunctiva, that the majority of T-Cells, 
both CD8+ and CD4+ cells are resident T cells and split into two distinct groups, 
the largest expressing CD69+CD103+. In addition, there is a smaller population 
of CD4+ CD25+ FoxP3+ cells which can be demonstrated in the conjunctiva 
and, in response to viral infections, these cell have been shown to supress 
effector T-cells110 acting as T-reg. 
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In the skin, two circulating subsets and two resident subsets of resident memory 
cells, with the effector functions of resident cells higher than recirculating 
cells.111 
Macrophages in the Ocular Surface 
Macrophages are phagocytic granular cells that are found throughout the 
tissues of the body. Their primary function is the clearance of pathogens, 
infected host cells and debris through phagocytosis. Macrophages are derived 
from circulating monocytes produced in by haemopoietic stem cells in the bone 
marrow, although in some circumstances it is possible for tissue macrophages 
to proliferate within tissues independent of recruitment from the circulation. 112 
Different macrophage subsets have been identified; M1 macrophages are 
classically activated and encourage inflammation; M2 macrophages are 
alternatively activated and are involved in tissue repair. Regulatory 
macrophages which are able to supress inflammation by secretion of the anti-
inflammatory cytokine IL-10, this is especially important in the gastrointestinal 
tract, where there is constant exposure to microbial products.113 Finally Tumour-
associated Macrophages and myeloid-derived suppressor cells (MDSC) , are 
immune suppressive cells which may inhibit anti-tumour activity.114  Debate 
exists as to the exact classification of monocyte derived cells and to whether 
antigen presentation is a function of dendritic cells or macrophages115  but 
macrophages play in role in antigen presentation and T-cell activation116.  
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The Lacrimal Gland 
The lacrimal glands are paired exocrine glands situated in the lateral aspect of 
the roof of the orbit sitting in a depression of the frontal bone, the lacrimal fossa. 
The lacrimal gland is a compound tubulo-acinar gland, histologically consisting 
of multiple lobuli draining into an intralobular duct. Multiple intralobular ducts 
then drain into interlobular ducts, which in turn, drain into 5-7 ducts, which then 
enter the ocular surface.  
As early as 1976, plasma cells were demonstrated in the lacrimal gland. 117 In 
the ageing, healthy lacrimal gland, lymphocytosis is frequently seen and are 
more commonly found in the orbital portion of the gland. 118 Lacrimal gland 
enlargement is a common finding in patients with Primary Sjögren’s Syndrome 
(pSS) and lacrimal gland lymphocytosis is a hallmark of pSS. 119 In the MRL/lpr 
mouse model of pSS resident epithelial cells have been shown to express 
ICAM-1, facilitating lymphocyte migration.120 
The Lids and Meibomian Glands 
The Lids 
The eyelids are highly specialised tissues that have evolved to protect and so 
maintain ocular surface integrity. The eyelids serve a number of functions, all of 
which support the ocular surface and tear film and hence vision. Firstly, the 
eyelids act as a physical barrier, protecting the eye not only from physical 
damage, but from excess light and heat. A row of eyelashes protect the ocular 
surface from debris, and initiate the blink reflex.  
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In order for the tear film to act as a reliable refractive surface, it is vital that the 
tear film is smooth and even; the eyelids play a pivotal role in maintaining a 
consistent tear film. Each blink helps to redistribute the tear film, in particular 
redistributing the lipid tear film (see below). In addition to constantly 
redistributing the tear film, the eyelids act as a lacrimal pump to help remove 
tears from the tear film. Through action of the orbicularis muscle on the lacrimal 
sac, each blink compresses the sac, creating a negative pressure and ‘sucking’ 
tears into the canaliculi and out of the ocular surface. 
Within the eyelid is a fibrous plate, the tarsal plate, which provides the lid with 
rigidity. These glands are responsible for producing meibum, a complex mixture 
of lipid species which form the lipid portion of the tear film. Spontaneous Blink 
Rate varies between individuals and increases with age121 but is approximately 
20 blinks/minute for an adult.  
The Meibomian Glands 
Within the tarsal plate is a row of modified sebaceous glands, first described by 
the German physician Heinrich Meibom in the 17th Century, and later named 
Meibomian Glands. They secrete a complex mixture of lipid species; these form 
the lipid layer of the tear film. Dysfunction of the glands, and subsequent 




Vital dyes are commonly used in clinical examination of the ocular surface; a 
number of vital dyes have been used clinically, including fluorescein and 
lissamine green. When such dyes are instilled, a clear, thin line becomes visible 
on the lid margin (Figure 6). This was first noted by Marx in 1924122 and  
represents barrier line, delineating where the lipids forming the lipid tear film, 
meet the aqueous layer of the tear film. Marx’s line is known to change with 
age, and with disease that affects Meibomian gland function. 9 
 
Epidemiology of Ocular GvHD 
Exact figures on the incidence of ocular GvHD are complicated by changes in 
conditioning regimen, as total body irradiation may increase the risk of dry eye 
disease123, by treatments to prevent systemic GvHD124, and the indications for 
HSCT, as those with a diagnosis of a haematological malignancy are more at 
risk. 124 
Figure 6 The lower eyelid margin, stained with fluorescein, lissamine green and 
rose bengal to demonstrate Marx Line from Yamaguchi et al.9 MO – Meibomian 
orifices, Ml Marx line. 
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The more recent figures suggest an incidence of ocular GvHD of between 33-
50%.124-127 with severe ocular disease in 13% and a severe reduction of vision 
to less than 20/200 in 2%.128 
In the published literature, ocular GvHD is consistently more likely to be 
associated with systemic GvHD. Na et al124 found that all of the patients in their 
cohort with ocular disease had evidence of systemic cGvHD, other authors find 
have found a different proportions of 14%125, 38%129 and 50%128, 81%130. 
Furthermore, the likelihood of ocular GvHD may depend on the degree of 
systemic cGvHD; with ocular disease being more likely the more ‘non-ocular’ 
organs have cGvHD. 124It is important to note that the earlier literature is 
complicated by the inclusion of patients who have undergone TBI and that  this 
finding is universal with one author reporting no significant relationship between 
the presence of chronic systemic GvHD and ocular GvHD127.  
Interestingly there appears to be a relationship of the ocular disease with 
preceding acute systemic disease. A number of authors have found that the 
development of acute systemic GvHD increases the chance of subsequently 
developing ocular disease. 124,126,129  and as mentioned above, aGvHD 
increases the risk of subsequently developing systemic cGvHD. 49-55  
Gender mismatch has long been identified as risk factor for aGvHD131 and this 
has also been shown to be significant factor for the ocular disease, with ocular 
GvHD being more common in female to male transplants.126,132 This occurs 
even in fully MHC matched transplants and is believed to be due to mismatches 
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in minor histocompatibility antigens. 133 In particular, female donors have not 
been exposed to epitopes originating on the Y chromosome and thymic deletion 
would not have removed cells that recognise the H-Y antigens, increasing the 
risk of GvHD, and the benefits of GVL.134 
Most importantly, there is a significant impact in the quality of life in patients with 
ocular GvHD. Riemens et al135 used the VFQ25 to assess 54 patients with post 
HSCT and compared patients post-HSCT with ocular GvHD to patients post-
HSCT without ocular GvHD. The study found patients with ocular GvHD had 
significantly worse ocular pain, they found it significantly difficult to maintain 
their roles in life and they had significant difficulties in social functioning. 
Clinical Findings in Ocular GvHD 
GvHD can affect the eye and ocular adenexae in a number of ways, but the 
ocular surface disease is by far the most common. Table 7 lists the ocular 




Anterior Segment Chronic Keratoconjunctivitis Sicca 
 Chronic Cicatrising Conjunctivitis 
 Acute Pseudomembranous 
Conjunctivitis 
Inflammatory Chronic Anterior Uveitis136 
 Chronic Posterior Scleritis137 
Posterior 
Segment 
Chronic GvHD Retinopathy138 
 Chronic Central Serous Retinopathy139 
Table 7 The different Ocular Manifestations of Acute and Chronic GvHD. Whilst ocular 
surface is the most common, less common manifestations have also been described in 
the literature. 
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Pathogenesis of GvHD affecting the Ocular Surface and Lacrimal Apparatus 
Ocular Surface GvHD 
In 1983, Jabs et al 8 described the histological features of conjunctival biopsies 
and ocular tissue obtained at autopsy from 19 post-HSCT patients, with seven 
samples from six patients with clinical evidence of ocular acute or chronic 
GvHD. The prominent feature on light microscopy was conjunctival 
keratinisation, which was present in five specimens, each in patients with either 
acute or chronic GvHD. A lymphocytic infiltrate was demonstrated (Figure 7), 
but only in two patients, both with acute GvHD and pseudomembranous 
conjunctivitis. 
Rojas et al140, examined conjunctival biopsies with immunohistochemical 
techniques of patients before and after allogenic and autologous HSCT and in 
patients with and without GvHD related KCS. In all patients following HSCT, 
they found increased numbers of both CD4+ and CD8+ lymphocytes, and 
CD14+ cells. In both autologous and allogenic HSCT patients with dry eye, they 
found increased numbers of CD14+ cells. They were not able to further 
Figure 7 Bullous Separation of 
conjunctival epithelium with 
migration of lymphocytes into 
basal layer from Jabs et al.8 
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phenotype the CD14+ cells. Auw-Haedrich et al141  also used 
immunohistochemistry to compare patients with ocular GvHD with healthy 
controls. They found an increased number of CD8+ cells in the conjunctiva, but 
did not proved a statistical analysis of the numbers. Tatemastsu et al94 also 
used immunohistochemistry, but using impression cytology and, in addition to 
squamous metaplasia of the mucosal microvilli , they demonstrated CD8+ cells 
in the basal epithelium of patients with ocular GvHD, but not in patients with SS 
or healthy volunteers. Eberwein et al142 also demonstrated the presence of 
CD8+ in impression cytology samples, but when compared to the numbers in 
healthy volunteers, this failed to meet statistical significance. 
Herretes et al5 have shown in a mouse models of ocular GvHD found increased 
CD4+ and CD8+ cells in the conjunctiva. Furthermore, they used fluorescent 
labelled cells for the HSCT, and so were able to identify the CD4+ and CD8+T-
cells as originating from the donor. Interestingly the presence of infiltrating 
donor T-cells occurred before the onset of ocular disease. furthermore, they 
were able to determine that these infiltrating T-cells originated predominantly 
from the transplanted donor T-cells rather than from reconstitution of 
transplanted haemopoietic cells. In addition to lymphocyte populations in the 
ocular surface of mice with ocular disease, Herretes et al also identified the 
presence of CD11b+ mononuclear cells and neutrophils. 
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Lacrimal Gland GvHD 
Jabs et al8  also described the lacrimal gland features using tissue obtained at 
autopsy. They found accumulation of PAS-positive material and lacrimal stasis 
and occlusion and obliteration of the lumen of the acini. They do not report on 
any cellular infiltrate of the lacrimal glands. 
The lacrimal gland findings in ocular GvHD have been further described in both 
the human4 and the mouse model5.  The cellular infiltrate is composed of 
lymphocytes, macrophages and fibroblasts and is consistent in both the human 
(Figure 8 and Figure 9) and the mouse model (Figure 10).. These lymphocytes 
were subsequently further characterized as predominantly T-cells, both 
CD4+and CD8+cells with predominantly CD4+infiltrates and a smaller number 
of B-cells. 3 Furthermore, electron microscopy has demonstrated cellular 
Figure 8 Immunohistochemistry of lacrimal gland 
from patient with ocGVHD demonstrating periductal 
infiltrate of CD34+ fibroblasts, CD4+ and CD8+cells 
from Ogawa et al.3 
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interaction between macrophages and fibroblasts (Figure 9). in the lacrimal 
gland of patients with ocular GvHD.4 
This picture is remarkably similar to the lacrimal gland findings in Sjögren’s 
syndrome, which is also characterised by CD4+ lymphocytes, CD8+ 
lymphocytes, macrophages and a smaller population of B-cells. Thus the 
lacrimal gland, in both diseases, contains the pre-requisite cells to initiate a B-
cells response; antigen presentation, and T-cell activation. B-cells have been 
heavily implicated in GvHD with early reports of successful treatment with anti-
B-cell therapies such as anti-CD20 antibody (rituximab) 143 being later 
confirmed in larger prospective trials. 144,145 These findings are similar to the 
findings in salivary gland cGvHD. 
 
1I). An increase in the number of CD341 fibroblasts was more
prominent in patients with severe dry eye than in those with
mild dry eye. There were CD341 cells in the walls of small
blood vessels, and those cells appeared to be endothelial cells.
Laminin staining revealed multilayered and thickened basal
lamina around ducts (Fig. 1J). The basal laminae of blood
vessels were also multilayered in all patients with chronic
GVHD.
Electron Microscopic Findings
On initial overview of lacrimal gland specimens from patients
with chronic GVHD by electron microscopy, we noted an
increased number of fibroblasts in a collagenous matrix of the
interlobular stroma. In addition, we found a number of lym-
phocytes around ducts and sometimes in ductal epithelia (Figs.
2A, 2B). Therefore, we focused on stromal fibroblasts and
lymphocytes located in the periductal areas and the changes in
the basal laminae of ducts and blood vessels.
Stromal Fibroblasts
Stromal fibroblasts in the lacrimal gland had abundant, well-
developed, rough endoplasmic reticula and Golgi apparati
(Figs. 2A, 2B, 2C). Subplasmalemmal linear densities (i.e., cell-
to-matrix junctions having a lamina-like structure,20,21) were
observed on the surface of fibroblasts in two patients (Fig. 2C,
arrowhead and inset). Fibroblasts were attached to various
types of inflammatory cells, including lymphocytes (Figs. 2A
through 2F), macrophages (Fig. 2E), plasma cells, and myoep-
ithelial cells (Fig. 2G). Primitive or rudimentary contacts be-
tween fibroblasts and inflammatory cells were frequently ob-
served around ducts and vessels (Figs. 2C through 2F, 2F
inset)–i.e., closely apposed plasma membranes that were sep-
arated by a narrow interspace and an electron-dense amor-
phous material was visible near the membrane surface of the
apposed membranes.22 In the high-magnification view of the
area within the square in Figure 2B, a cytoplasmic processes
from the myoepithelial cell was attached to interlobular fibro-
blasts through the disrupted basal laminae (Fig. 2G). The myo-
epithelial cell was attached, through a number of primitive
contacts, to a lymphocyte that had infiltrated the acinus (Fig.
2G, arrowheads).
Newly synthesized fine collagen fibrils, distinguished from
more mature collagen fibrils by their shorter diameter, were
frequently observed in the extracellular matrix (Fig. 2H). The
FIGURE 2. Electron microscopic find-
ings in the lacrimal glands in patients
with chronic GVHD. (A) Interlobular
stroma shows infiltration of fibro-
blasts and lymphocytes in the collag-
enous matrix (case 1). (B) Stromal
fibroblasts increase in number
around a medium-sized duct. A lym-
phocyte is found in ductal epithelia
(case 4). A high-magnification view
of the area within the square is
shown in (G). (C) Subplasmalemmal
linear densities are observed on the
surface of fibroblasts (arrowhead
and inset; case 1). T cells with clus-
tered dense bodies (star) have infil-
trated the periductal areas and at-
tached to fibroblasts. (D) T cells with
clustered dense bodies (star) in the
periductal areas are attached to one
another (arrowheads) and to fibro-
blasts (arrows) through primitive
contacts (case 1). (E) Lymphocyte
and macrophages attached to fibro-
blasts in the perivascular area (case
1). (F) A primitive contact between a
fibroblast and a lymphocyte (case
4). Inset: Typical primitive contact
(arrow).
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Figure 9 Electron microscopy of human lacrimal gland in patient 
with ocular GVHD d monstrating lymphocyte a d m crophages 
ttached to fibroblasts in the perivascular area - Inset: Typical 
primitive contact (arrow). Ogawa et al 20014 
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Tear Film Findings in Ocular GvHD 
Riemens et al146 used multiplex cytokine bead array to examine the tears of 
patients with and without ocular GvHD and compared them to healthy 
volunteers. They looked at six cytokines; IL-2, IL-4, IL-6, IL17A, TNF-a, and 
INF-g and found increased levels of IL-6 and TNF-a in patients with ocular 
GvHD when compared with both post-HSCT patients without eye disease and 
healthy volunteers. 
Jung et al147 performed a similar study, also using multiplex cytokine bead 
array, looking for IL-2, IL-6, IL-10, IL-4, INF-g and TNF-a, in patients with 
cGvHD (as defined by NIH criteria2) which importantly includes ocular GvHD as 
part of the criteria. Ocular disease was assessed using a number of criteria 
including ocular surface staining, TBUT, Schirmer’s score, conjunctival injection 
and OSDI. They found evidence of increased levels of all tear cytokine levels 
except IL-4 in patients with systemic GvHD. In patients with signs of ocular 
sion. Each treatment is represented as relative expression (i.e.,
fold expression over reference group), where the control
sample served as the reference with a set value of 1. Primer










The unpaired t-test was used to compare between control and
experimental for fluorescein staining and conjunctival goblet
cell score. Both eyes were evaluated for ocular surface staining,
and the eye with the worse fluorescein staining score was
selected for statistical analysis (note that the data were also
statistically significant including both eyes or using the least
affected eye). A P value of 0.05 was considered statistically
significant. GraphPad Prism 5 (GraphPad Software, San Diego,
CA, USA) was used for the analyses.
RESULTS
Clinical Ocular Changes in Recipients Undergoing
GVHD in an Major Histocompatibility Complex
(MHC)-Matched, Minor Transplantation Antigen-
Mismatched Allogeneic Hematopoietic Stem Cell
Transplant Model
MHC-matched (H2b) C3H.SW mice were lethally conditioned
and several hours later received donor B6 BMCs replete with
B6 T cells (Table). Several weeks post HSCT, animals receiving
donor T cells lost weight and began to exhibit clinical signs
characteristic of GVHD including ruffled fur, hunching, and
diarrhea (Figs. 1A–C). Recipients were examined for additional
immunologic phenotypes characteristic of GVHD including
decreased splenic cell numbers and diminished B cells (Figs.
1 , 1E). To monitor for changes in the ocular surface in
recipients of HSCT, animals were anaesthetized and the corneal
surface was assessed by clinical examination and fluorescein
staining. Approximately 3 to 4 weeks following transplanta-
tion, increased fluorescein staining was observed only in the
cornea of recipient mice that received donor T cells, and this
progressed to corneal ulcerative lesions by ~6 weeks (Fig. 2A).
Quantitative analyses for corneal staining and clinical changes
demonstrated a difference in the tempo of induction between
systemic and ocular GVHD (Fig. 2B).
FIGURE 4. Involvement of the ocular adnexa in mice with GVHD. (A) Photographs (PAS-stained, 7-lm sections, 320) of the central superior
conjunctiva of mice receiving B6 TCD-BM only or together with B6 T cells, where goblet cells stain dark pink (black arrow). Mice with GVHD
exhibited thickening and irregularity of the basal membrane, as well as atrophy and reduced number of goblet cells (B). (C) Photographs of lacrimal
gland histology from mice receiving TCD-BM only or together with T cells. Sections are 7 lm thick and stained with H&E at 320 magnification.
Periductal fibrosis, dense cellular infiltrates (black arrow), and stasis of secretions in ducts (arrowheads) are observed in lacrimal glands of animals
with systemic GVHD.
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Figure 10 Histological and Immunohistochemical slide from lacrimal gland of 
mouse model of ocul r GVHD demonstra i g lacrimal gland tasis (arrowhead) 
and a dense cellular infiltrate composed of CD11b, CD4 and CD8 cells Herretes 
et al.5 
CD11b CD8 CD4 
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GvHD, they again found increases in levels of all cytokines, except IL-4, with a 
stronger correlation for for IL-6, IL-10 and TNF-a (r>0.4). 
Dry Eye Disease 
Definition of Dry Eye Disease 
The DEWS II report defines dry eye disease as148 
“Dry eye is a multifactorial disease of the ocular surface charac- 
terized by a loss of homeostasis of the tear film, and accompanied 
by ocular symptoms, in which tear film instability and hyper- 
osmolarity, ocular surface inflammation and damage, and neuro- 
sensory abnormalities play etiological roles.” 
This definition attempts to describe the complex nature of both the 
symptomatology and pathophysiology of dry eye disease. Multiple clinical 
entities with similar clinical features are encompassed in the dry eye syndrome. 
Classification 
The 2007 DEWS report64 classifies the causes of Dry Eye Disease into two 
main categories, aqueous deficient dry eye disease (ADDE) and evaporative 
dry eye disease (EDE). This was refined by the DEWS II report149 which 
considers dry eye disease to exist on a spectrum with pure ADDE and pure 
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EDE on each end, with a continuum of mixed dry eye disease in between 
(Figure 11). 
 
Figure 11 DEWS II Aetiological Classification of Dry Eye Disease from 2017 DEWS II 
report. Note how dry eye can manifest as a number of clinical entities, all requiring a 
tailored approach to treatment. 
Aqueous Deficient Dry Eye Disease (ADDE) and Sjögren's Syndrome 
In ADDE, there is insufficient production of the aqueous component of the tear 
film. The classical form of ADDE occurs in Primary Sjögren’s Syndrome (pSS); 
where autoimmune mediated inflammation causes fibrosis of the lacrimal gland 
and other exocrine glands, such as the salivary gland. Lacrimal gland biopsies 
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of patient with Sjögren's have demonstrated lymphocytosis with predominantly 
CD4+cells and B-cells150; although CD8+cells and antigen presenting cells have 
also been demonstrated. 150 The resultant fibrosis results in reduced tear 
production and subsequent ADDE. The lacrimal gland damage in ocular GvHD 
is very similar, albeit with a different cause: in ocular GvHD the immune 
mediated damage to the lacrimal gland is incited by donor alloreactive cells 
causing ADDE.  
Evaporative 
Deficits in the lipid tear film, also cause dry eye syndrome despite an adequate 
tear production. In EDE, abnormalities in the lipid tear film, allow rapid 
evaporation of the tear film and reduced tear stability. EDE can be intrinsic or 
extrinsic depending on the causes. Intrinsic dry eye disease includes 
Meibomian gland dysfunction, disorders of lid anatomy, low blink rate; extrinsic 
causes include vitamin A deficiency, topical drugs/preservatives, contact lens 
wear, or ocular surface disease. 
The Tear Film 
Classically the tear film has been described as a tri-laminar structure151 
composed of three layers. 
1. Lipid Layer 
2. Aqueous Layer 
3. Mucin Layer 
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The lipid layer, secreted by the Meibomian glands, ‘floats’ on the surface of the 
tear film, preventing tear evaporation. The aqueous layer, constitutes the 
majority of the tear film, and is secreted by the lacrimal glands, and accessory 
lacrimal glands. The mucin layer is secreted by the epithelium of the cornea and 
conjunctiva, and enables interaction between the cellular epithelium and the 
aqueous tear film. More recently, it has become apparent that this is an 
oversimplification. Rather than separate layers, the mucin layer represents a 
gradient of mucous components152, more concentrated at the epithelial surface, 
and diluting superficially. This had led to the concept of a single mucoaqueous 
layer. In-vitro studies have demonstrated that contrary to the classical model, 
the thickness of the lipid layer may not affect the evaporation rate of tears153 
leading some authors to suggest the role of the lipid tear film is to allow smooth 
distribution of the tear film, rather than to prevent evaporation.154 
Pathophysiology of Dry Eye Disease 
Clarity of the ocular media is a pre-requisite for vision and maintenance of this 
clarity is a vital function of the ocular surface. Inflammation related damage to 
the ocular media risks this clarity and, even with successful clearance of the 
inciting agent, would lead to permanent scarring and loss of vision. A number of 
mechanisms have evolved within the eye to limit inflammation and so limit 
inflammation induced damage, and the ocular surface is no exception.  
A number of anti-inflammatory cytokines are found in the tears of healthy 
volunteers. Including interleukin -1 receptor antagonist (IL-1-RA)155, 
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transforming growth factor beta (TGF-beta)156, IL-10155, IL-13155, Tissue Inhibitor 
of Metalloproteinase-1 (TIMP-1)157,  programmed death-ligand 1 (PD-1-L1)158, 
decay accelerating factor (DAF)159 and membrane inhibitor of reactive lysis 
(MIRL).160 TGF-β in both the tears and released by Goblet cells161, has been 
shown to suppress dendritic cell (DC) maturation on the ocular surface, 
reducing expression of co-stimulatory molecules, and reducing DC stimulation 
of T-cells.162  DAF and MIRL are membrane bound proteins that protects from 
complement activation, and the presence of both have been demonstrated in 
both the lacrimal gland and the corneal epithelium. 159,160  
As mentioned above, the ocular surface contains a population of intraepithelial 
lymphocytes (IEL),163  and amongst these cells exists a population of T-reg cells 
(CD4+ CD25+ FoxP3+) which can supress effector T-cells.110 NKT cells are 
also found on the ocular surface, and, through the release of IL-13, protect 
goblet cells164 and hence maintain suppression of dendritic cells maturation.161 
As discussed above a number of possible mechanisms exist to produce dry eye 
disease. In ocular GvHD, the mechanism behind the keratoconjunctivitis sicca, 
primarily involves aqueous deficiency from lacrimal gland involvement. A 
common point in the pathophysiology of all forms of dry eye, is hyperosmolarity 
which results in a number of changes in the ocular surface. Desiccating stress 
has been shown to affect a number of cell populations in the eye, including 
epithelial cells, Goblet cells and antigen presenting cells. Epithelial cells 
respond to desiccating stress by activation of the NF-kappa-beta and MAPK 
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pathways resulting in the release of inflammatory mediators including IL-1beta, 
TNF-a and MMP-9.165 Furthermore, IL-6 and IL-8 are not only produced by 
human cultured epithelial cells, but also may be implicated in epithelial cell 
death. 166 Goblet cell death results in reduced production of TGF-beta, allowing 
DC maturation. Bone marrow derived cells upregulate chemokine receptors, in 
particular CCR5. 167 
Activation of Pattern Recognition receptors, such as TLR4, encourages 
CD11b+ monocyte infiltration.168. Additionally, epithelial cell apoptosis releases 
DNA in of dry eye disease169, and TLR receptors have been shown to react to 
endogenous DNA in autoimmune disease, such as Sjogren’s Syndrome.170. 
Monocytes have been shown to play a role in dry eye disease171 and are 
increased as disease severity increases172; bridging the innate and adaptive 
immune system, acting as APC and encouraging and maintaining T-cells 
infiltration at the ocular surface. 173 Although some authors have not found an 
increase in the number of macrophages, instead suggesting that a change in 
the relative subtypes of macrophages may be more important.174 NK cells are 
seen early in the dry eye response and their depletion ameliorates desiccating 
stress damage in the animal model. 175  
As result of the innate response, the efferent arm of the response adaptive 
response is by T-cells, CD4+cells found in the conjunctiva of patients with dry 
eye, 176 and transfer of CD4+T-cells isolated from mice exposed to desiccating 
stress will cause dry eye in T-cell depleted mice. 177  Further work has heavily 
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implicated Th17 cells as drivers of dry eye disease. Th17 cells are activated in 
secondary lymphoid tissues which subsequently migrate to ocular surface and 
induce further immune responses.178 Locally, Th17 differentiation may well be 
occurring on the ocular surface, as in vitro co-culture of naïve CD4+cells can 
induce Th17 polarization.179 
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Hypothesis and Aims 
Hypothesis 
Firstly, we propose that there is cycling of immunocompetent cells in the 
conjunctiva and these cells will be reconstituted following bone marrow 
transplantation. 
Secondly we propose that in ocular GvHD, there is Graft-vs-Host response, in 
the ocular surface that is independent of the aqueous deficient dry eye disease 
caused by lacrimal gland fibrosis and destruction.  
Aims 
In this study, we aim to describe how the ocular surface leukocyte populations 
reconstitute following HSCT and how this differs from leukocyte reconstitution in 
the blood and from the conjunctival leukocyte populations in healthy volunteers. 
Secondly, we aim to describe how the conjunctival leukocyte populations in 
patients with ocular GvHD differs from that in patients without ocular disease, 
healthy volunteers and in patients with pSS. 
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Materials and Methods 
Clinical Studies 
Ethical Approval 
Clinical data collection and patient sampling were undertaken following ethical 
approval and in accordance with the Declaration of Helsinki. Ethical approval for 
recruitment, examination and sampling from all patients was obtained through 
the West Midlands - Black Country research ethics committee (Reference 
11/WM/0204). 
Clinical Examination  
For each Cross-Sectional and Longitudinal Cohort patient, a standardised 
clinical assessment was performed. 
Three questionnaires were given to the patient to self-complete; on the impact 
of the transplant on the patient (FACT-BMT v4), on the quality of the patients 
visual function (National Eye Institute Visual Function Questionnaire 25), and 
finally a questionnaire on the severity of the dry eye symptoms9 (OSDI, 
Allergan). 
The patient’s visual acuity was measured using logMAR chart. Tear osmolarity 
was measured using a Tearlab (TearLab Corp., San Diego, CA). Local 
anaesthetic was instilled (Oxybuprocaine 0.4% minims, Bausch and Lomb) and 
Ocular Surface Impression Cytology (OSIC) was performed as per below. 
51 
Unanaesthetised Schirmer’s testing was performed for five minutes. Slit lamp 
biomicroscopy was performed with a standardised protocol. Lid examination 
included assessment for Meibomian gland changes using a modified version of 
the schema set out by Bron et al180 concentrating on those features that might 
alter in cicatrising disease (Table 8).  
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Anatomical Structure Measure Scoring 
Eyelid Margin Irregularity 0. No 
1. Yes 
Vascularity 0. No 
1. Yes 






Which? • Trichiasis 
• Dystichiasis 
Malapposition 0. No 
1. Yes 
Anterior Blepharitis 0. No 
1. Yes 
Mucocutaneous junction Anteroplacement 0 - 3 
Retroplacement 0 - 3 
Ridging 0 - 3 
Mucosal Absorption 0. No 
1. Yes 
Orifices Pouting or plugging 0. No 
1. Yes 
Opaque/scarred 0. No 
1. Yes 
Retroplacement 0 - 3 
Main Duct Cystoid Dilatation 0 - 3 
Acini Visibility • Clusters 
• Yellow stripes 
• Not Visible 
Concretions • Deep 
• Subepithelial 
• Extruding 
Chalazia 0 - 3 
Secretions Foam 0. No 
1. Yes 




Expressability • Light pressure 
• Moderate pressure 
• Heavy pressure 
Table 8 Modified Bron Schema for the Scoring of Meibomian Gland Changes 
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Vital dye staining was performed using Lissamine Green and Fluorescein. Tear 
Break Up Time (TBUT) was measured at the slit lamp. An assessment of 
Marx’s line was performed using the scoring system described Yamaguchi et 
al.9  Briefly this score assesses posterior migration of the Meibomian gland 
orifices on a scale of 0-9 with higher scores indicating more marked posterior 
orifice migrations. Conjunctival and corneal staining was assessed using a 
modified Oxford Score.181 Conjunctival fibrosis was assessed using the grading 




a quarter of the patients able to discontinue all systemic
immunosuppressive medications. The high ocular drug
concentrations that can be achieved with topical cortico-
steroids compared with systemic administration24 can
promote lymphocyte apoptosis and suppress cell-mediated
inflammation.25,26 This is of special relevance in patients
with ocular GVHD where the primary inflammatory cell
present histologically is the T lymphocyte.9,27,28 However,
treating patients with topical ocular corticosteroids must be
managed by an ophthalmologist to monitor for sight-
threatening conditions such as corticosteroid-induced
glaucoma, cataracts, infectious keratitis, and corneal
thinning.29,30
The pathogenesis of cicatricial conjunctivitis associated
with GVHD is not clear but may represent a response to
tissue injury associated with conjunctival sloughing and
ulceration. Patients with skin and oral mucosal GVHD
develop a similar pattern of tissue injury that may result in
tissue ulceration and fibrovascularization in the chronic
stages.21 The location of the inflammatory and cicatricial
changes, starting most commonly along the superior border
of the tarsus in the upper eyelids, may be important in the
pathogenesis of the aqueous tear deficiency seen with KCS
in GVHD patients. The assessory lacrimal glands located in
this area contribute significantly to basal tear production31
and become involved early in the inflammatory process.8 In
case 1, the patient had aqueous tear deficiency that was
reversed with the use of topical ocular corticosteroids.
However, the other cases had either long-standing aqueous
tear dysfunction or extensive inflammatory changes likely
resulting in assessory lacrimal gland injury not recoverable
with topical corticosteroid therapy.
Figure 1 Representative external photographs of everted upper and lower eyelids showing the different grades of conjunctival inflammation associate with
chronic GVHD. Arrows indicate the more subtle cicatricial changes seen in Grade 2.
Figure 2 (a) Case 1: external photograph of an everted left upper eyelid showing Grade 2 conjunctival GVHD before topical ocular corticosteroid
treatment. Fibrovascular changes are present (arrows). (b) Case 1: external photograph of an everted left upper eyelid 4 weeks following topical ocular
corticosteroid treatment. Note resolution of the conjunctival hyperemia and areas of inactive scarring. (c) Case 2: external photograph of an everted right
upper eyelid showing Grade 3 conjunctival GVHD before topical ocular corticosteroid treatment. (d) Case 2: external photograph of an everted right upper
eyelid 4 weeks following topical ocular corticosteroid treatment. No residual conjunctival fibrovascularization is apparent.
Topical therapy for cicatricial conjunctivitis
MR Robinson et al
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Bone Marrow Transplantation
Figure 12 F om Robinson et al 1. Representative grading photos for c nju ctival 
Inflammation associated with chronic GVHD. Arrows illustrate the subtle cicatricial 
changes associated with Grade 2. 
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Ocular Surface Staining was assessed using a modified version of the Oxford 
staining system by Bron et al181. This system separates the ocular surface into 5 
corneal areas, and two pairs of 3 conjunctival areas, nasal and temporal (Figure 
13). The degree of staining is compared to mathematically defined grading 






Figure 13 Diagram to show how the ocular surface is subdivided in the modified Oxford 
Schema. The cornea is divided into 5 sections, including the visual axis. The medial and 




Figure 14 Mathematically random dot patterns used to describe the severity of ocular 
surface staining in each area of the ocular surface. Each panel contains a randomly 
generated dot pattern with increasing density. 
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OSIC Sampling Method 
Ocular Surface Impression Cytology (OSIC) was performed according to 
techniques first described by Baudoin et al182.  Supor 200 polyethersulfone 
filters (Supor® 200 membrane, Pall Corporation, Ann Arbor, MI, USA) were 
bisected and autoclaved; four halves were used, resulting in a total sampling 
area of 264mm2.  
Before patient sampling, experiments on healthy volunteers demonstrated that 
conjunctival impression sampling after the use of lissamine green, a vital dye 
used in clinical examination, can affect subsequent flow cytometry due to 
fluorescent interference from the lissamine green183 (Appendix 1 Use of 
lissamine green before conjunctival impression cytology and flow cytometry in 
patients with Sjögren’s syndrome). Sampling was therefore performed before 
clinical examination. Topical anaesthesia was instilled into the subject’s fornix 
and two bisected haves were placed onto the superior bulbar conjunctiva and 
Figure 15 Ocular Surface Impression Cytology with 
Supor 200 filter 
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two were placed on the inferior bulbar conjunctiva, each for 3-5 seconds (Figure 
15). Care was taken to avoid the interpalpebral area, in order to avoid iatrogenic 
changes that might be confused with pathological conjunctival staining on 
subsequent slit lamp biomicroscopy examination. 
During the study, a new purpose designed device was introduced for 
conjunctival impression cytology. The EyePRIM (Opia Technologies, Paris, 
France) contains a polyethersulphone (PES) supor filter with an area of 69mm2 
mounted in a single use device (Figure 16). Experimentation on healthy 
volunteers demonstrated that OSIC was quicker and less painful using the 
EyePRIM, with no difference in cellular yields when two EyePRIM devices were 
used (total area 138mm2) compared with four bisected halves of a supor 200 
filter (total sampling area 264mm2).184 
Figure 16 Ocular Surface Impression Cytology with the EyePRIM device 
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Immediately following sampling, the filter papers were placed directly into tissue 
culture medium (1.5ml of RPMI 1640 (Sigma-Aldrich, Dorset, UK) enriched with 
10% Heat Inactivated Foetal Calf Serum (HIFCS) (Sigma-Aldrich) in a sterile 
5ml bijou.  
Ex vivo experimentation 
Conjunctival Cell Recovery  
Samples were processed within 5 hours of sampling. Conjunctival cells were 
removed from the Supor filter by gentle agitation with a sterile 1ml pipette tip for 
1 minute whilst the filter paper was still suspended in RPMI/HIFCS. 
The tissue culture medium, containing the suspended cells, was removed and 
centrifuged. The supernatant was discarded and the cell pellet resuspended in 
90µl tissue culture medium to give a working volume of approximately 100µl 
and pipetted into 96 well plates in preparation for immunostaining. 
Lysed Blood Preparation 
Venepuncture was performed, into K2 EDTA coated vacutainers (Becton 
Dickinson, Oxford, United Kingdom). 1ml of whole blood was centrifuged and 
the plasma removed and discarded. Red cell lysis was performed with 9ml (1:10 
dilution) of ACK buffer (consisting of 8.29g NH4Cl, 1g KHCO3 and 37.2 mg 
EDTA per litre) was added for 5 minutes. To stop continued lysis, 15ml of RPMI 
medium was added. Samples were then centrifuged, the supernatant discarded 
and the pellet resuspended with 10ml PBS. Samples were centrifuged for a 
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second time, again the supernatant discarded and the pellet resuspended in 
1ml PBS. 
Antibody Staining 
100 microl of cells were pipetted in to 96-well plates aiming for a cell count per 
well of 2x105—1x106 for PBMCs). The plate was centrifuged (4 minutes at 400g 
at 4C), the supernatant was removed and the 96-well plate gently vortexed. 
Antibodies specific for a number of surface markers (Table 9) were made up to 
50µl appropriate dilutions (optimal antibody concentrations having been 
previously titrated) and incubated with the cells on ice in the dark for 20 
minutes. Post-staining, 100µl of FACS buffer (PBS and 0.5% Bovine Serum 
Albumin (BSA; Sigma- Aldrich) was added to each well and the plate was 
centrifuged for a second time and the supernatant removed. The pellet was 
resuspended in 295µl of FACS buffer. To allow us to ascertain what proportion 
of the sample had been run through the flow cytometer, 5 µl of counting beads 
(CALTAG/Invitrogen, Paisley, UK) (1002 beads/ µl) were added.  
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Table 9 Antibody-fluorochrome combinations used for immunostaining of lysed blood 
and conjunctival impression samples. 
In order to exclude any dead or dying cells, a nucleic acid stain, Sytox blue 
(Invitrogen, Paisley, UK), was used that only permeates dead cells. 30µl of 
Sytox blue as added at a dilution of 1/800 to the FACS tubes and incubated for 
5 minutes at room temperature.  
Flow Cytometry 
Flow cytometry was performed with a nine colour Dako Cyan ADP High 
Performance flow cytometer (Beckman Coulter, High Wycombe, UK).  
Surface 
antibody 
 Fluourochrome Manufacturer 
CD11b Macrophage/Monocyte cell marker FITC Ebioscience, Hatfield, UK  
CD8a CD8+ Cytotoxic Lymphocytes VioGreen Miltenyl Biotec  
CD16 Macrophage/Monocyte cell marker PE Ebioscience, Hatfield, UK  
CD45RO 
Isotype of CD45 used 
to differentiate between 
naïve and mature T 
cells 
PE-CF594 BD BioSciences, Oxford, UK 
CD45 Pan-Leukocyte Marker APC Ebioscience, Hatfield, UK  
CD4 CD4+ T-Helper Lymphocytes PerCP-Cy5.5 Ebioscience, Hatfield, UK  
CD14 Neutrophil Marker APC-eFluor780 Ebioscience, Hatfield, UK  
CD3 Lymphocyte Marker APC-eFluor780 Ebioscience, Hatfield, UK  
CD56 NK and NKT marker PE-Cy7 Ebioscience, Hatfield, UK  
Sytox Blue Dead Cell Exclusion Dye  Invitrogen, Paisley, UK  
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Fluorescence Compensation 
One potential issue in multi-colour flow cytometry is overlapping fluorescent 
signals from fluorochromes emitting light in any adjacent spectra, which may be 
confused with another fluorochrome and hence cause falsely positive results. In 
order to avoid such fluorescence overlap, prior to each run of samples, a full 
electronic compensation panel was performed: consisting of a single 
fluorochrome incubated with positive and negative compensation beads 
(OneComp beads, EBioScience, Hatfield, UK). Any signal from a fluorochrome 
that overlaps into an adjacent spectrum is reduced. For example, if when the 
sample conjugated to PE is run through the flow cytometer, there is an 
overlapped fluorescence into the adjacent PE-Cy5 channel, then the PE-Cy5 
channel is reduced down, or compensated, to zero by subtracting a percentage 
of the PE fluorescence value. 
To allow compensation, each time a sample was run, 20 µl of positive and 
negative compensation beads were individually stained with each antibody-
fluorochrome combination alongside the immunostaining of sample cells. 
 Gating Strategy 
Lymphocyte Gating Strategy 
The gating strategy to isolate different lymphocyte populations in the 
conjunctiva is shown in Figure 17.The first step was to remove the counting 
beads and cellular debris (Figure 17A). The majority of cells on the OSIC are 
epithelial cells; in order to identify viable leukocytes, a pan-leukocyte marker, 
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CD45, and the dead cell exclusion dye was used (Figure 17B). We needed to 
identify lymphocytes CD3+ cells; since CD14 and CD3 were both using the 
same fluorochrome, CD45 was used. Lymphocytes were CD45bright (Figure 
17C) and to ensure only lymphocytes were included this population was back-
gated onto the forward scatter and side scatter plot (Figure 17D) with 
lymphocytes defined as cells with low granularity. CD4+ and CD8+ cells were 
then isolated (Figure 17E) and then further subdivided into CD45RO+ and 
CD45RO- populations. Natural Killer T-cells were defined as those living 
leukocytes (exclusion dye negative CD45+) CD3+ cells that expressed 








Forward Scatter and Side 
Scatter is used to identify the 
counting beads (area R19) 
and leukocytes selected in 
area R2. 
R2 is then gated to find the living 
(Sytox –ve) cells that are CD45+ 
(pan-leukocyte marker) in R3. 
Since CD3 (lymphocytes) and CD14 
(Monocytes) are on the same fluorochrome 
(APC-Cy7), lymphocytes are defined as 
CD45(high) and APC-CY7+ (R6). 
This is then backgated onto a Forward 
Scatter and Side Scatter Plot to ensure 
cells with a FS and SS typical of 







Lymphocytes are then 
phenotyped into CD4+ (R18) 
and CD8+ (R15). 
 
R8 (lymphocytes) are then 
gated to CD56, with NKT 
cells defined as CD56+ 
cells. 
Figure 17 Gating strategy to identify lymphocytes. A Counting beads are counted and cells identified 
excluding debris. B Sytox and CD45 (panleukocyte marker) used to find living leukocytes. C CD45high 
(CD3+ lymphocytes) and CD45dim (CD14+ cells) on the same fluorochrome are defined. D This is then 
backgated onto FS and SS to ensure only lymphocyte shaped cells are included. E CD4 and CD8 
lymphocytes are subdivided. F CD56 is used to describe NKT cells. 
A 
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Gating Strategy for monocytes, NK cells and neutrophils 
Since the numbers of conjunctival leukocytes were small, gating was first 
performed on lysed blood and then these gates used to help define the 
conjunctival cells. Figure 18 shows the gating strategy for both NK cells and 
neutrophils. As before, cells were initially isolated from debris (Figure 18A) and 
counting beads and living leukocytes isolated by using the pan-leukocyte 
marker CD45 and the dead cell exclusion dye (Figure 18B). These cells were 
then defined as NK cells if they were CD56+ (Figure 18C) or neutrophils if they 
were CD11b+ and CD16+ (Figure 18D). The gating strategy for monocytes is 
shown in Figure 19.Monocytes were defined as those cells that are living 
leukocytes (exclusion dye negative CD45+) and that were CD14+. Since CD14 
and CD3 shared a fluorochrome, monocytes were defined as those cells that 
were less bright on CD45 and these cells were further backgated onto FS and 
SS to further differentiate these cells from lymphocytes. This was then 




Forward Scatter and Side Scatter is 
used to identify the counting beads 
(area R19) and leukocytes selected 
















R2 is then gated to find the living 
(Sytox –ve) cells that are CD45+ 
(pan-leukocyte marker) in R3. 
R3 (living leukocytes) is then used to gate 
other NK cells and Neutrophils. 
NK cells are defined as 
cells which are CD56+ 
and CD3/CD14- (R7). 
Neutrophils are defined as 
cells which are CD16+ 






Figure 18 Gating Strategy for NK Cells and Neutrophils in a lysed blood sample. A  Counting beads are 
counted and cells identified excluding debris. B Sytox and CD45 (panleukocyte marker) used to find 





Forward Scatter (FS) and Side 
Scatter (SS) is used to identify the 
counting beads (area R19) and 
















R2 is then gated to find the living 
(Sytox –ve) cells that are CD45+ 
(pan-leukocyte marker) in R3. 
Since CD3 (lymphocytes) and CD14 
(monocytes) are on the same 
fluorochrome (APC-Cy7), monocytes are 
defined as CD45(dim) and APC-CY7+ 
(R13). 
This is then backgated onto a Forward 
Scatter and Side Scatter Plot to ensure 
cells with a FS and SS typical of 
lymphocytes are excluded. These cells 
are defined as monocytes (R15). 
B 
D 
Figure 19 Gating Strategy for Monocytes in Lysed Blood A  Counting beads are counted and cells 
identified excluding debris. B Sytox and CD45 (panleukocyte marker) used to find living leukocytes. C 
Since CD3 (lymphocytes) and CD14 (monocytes) were on the same marker, CD45 was used to 
separate CD45dim cells and these were then backgated D to ensure cells with a FS and SS profile 































FS and SS plot to 
exclude debris and 
counting beads.. 
Dead cells and non-
leukocytes are 
excluded (R3). 
R3 gated on CD56 to 
define NK cells.  
R3 gated on CD16 
and CD11 to define 
neutrophils. 
R3 gated on CD45 to 
define CD45dim cells 
(R13) 
R13 backgated to FS 
and SS to define 
monocytes. 
Figure 20 Gating strategy for NK cells, neutrophils and monocytes in a representative conjunctival 
sample. A shows FS and SS with R2 gating to include all cells, excluding counting beads and debris. B 
Cells from gate R2 that did not stain with the dead cell exclusion dye and were CD45 (pan-leukocyte 
marker) positive (R3). C is gated off R3 and shows NK cells (CD56 +h CD3/CD14-) D is also gated off R3 to 
show neutrophils (CD16+/CD11+) high and CD11b high and are defined as neutrophils. E Shows a subset 




For the longitudinal analysis, two way repeated measures ANOVA using 
Graphpad Prism v6.0h for MacOSX, GraphPad Software, San Diego California 
USA, www.graphpad.com were used.  
Cross-Sectional Cohort 
Since the NIH classification uses the mean Schirmer’s score of the two eyes, 
the mean number of cells in the patient’s two eyes were used for statistical 
analysis of patients in the Cross-Sectional Cohort. Mann-Whitney non-
parametric tests were then performed also using Graphpad Prism 6.0h. 
Weighted Kappa analysis using the NIH severity scale was performed using 
graphpad’s online Kappa calculator at 
http://www.graphpad.com/quickcalcs/kappa2/. Since the severity scale is a 
symptomatic scale, the worst eye was considered for Schirmer’s score. Since 
the Kappa score required equal sizes, when compared with Schirmer’s score 
and with the International Consensus Group proposed diagnostic criteria, the 
last two NIH severity groups (2 and 3) were combined.  
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Chapter 3 Longitudinal Cohort  
Patient Recruitment 
Patients were recruited from the haematology clinics at the Centre for Clinical 
Haematology at University Hospital Birmingham. All patients who were listed for 
allogenic HSCT between May 2012 and July 2012 . 
Patients were included if they were about to undergo allogenic HSCT; there 
were no restrictions on the indications or method of transplant. Patients were 
excluded if they had any history of pre-existing ocular inflammatory disease. 
Patients were seen for a total of five visits; a baseline visit before HSCT and at 
1 month, 3 months, 6 months and 12 months post-HSCT. At each visit a clinical 
assessment and ocular sampling (OSIC) and blood sampling was performed. 
Samples were stored on ice and flow cytometry was performed on the OSIC 
samples and lysed blood samples within 5 hours. 
A total of five participants were recruited. One participant passed away due to 
recurrence of their original disease after the 3-month visit. One participant was 
seen at baseline, but failed the pre-assessment process, and their transplant 
was delayed, missing the 1 months and 3-month visit. 
In order to compare leukocyte populations, five healthy volunteers were 
recruited; blood samples were taken and OSIC performed on nine eyes. There 
was no significant difference between the ages of the healthy volunteers and 
either the longitudinal cohort (Mann-Whitney p=0.3267) or the cross-sectional 
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cohort (Mann-Whitney p=0.2967). As a disease control, we recruited 
participants with Primary Sjögren’s Syndrome. This group was chosen, as it 
represents a paradigm of aqueous deficient dry eye disease, in which there is 
fibrosis and destruction of the lacrimal gland. It is therefore similar to the dry eye 
disease associated with ocular GvHD, with the difference that in ocular GvHD, 
there is an underlying systemic T-cell mediated graft versus host response, thus 
potentially allowing a distinction between GVHD mediated ocular surface 
inflammation and aqueous deficiency ocular surface inflammation.  Seven 
patients (10 eyes) with Sjögren’s syndrome were recruited from the Sjögren’s 
clinic at University Hospitals Birmingham NHS Trust. Six patients were female, 
this group was significantly older than the cross-sectional cohort (Mann-Whitney 
p=0.0002) with a median age of 65.5 years (range 59-75 years).  
Results 
Characteristics of Participants 
Of the five recruited participants, one participant was female and all participants 
were white. The mean age of the participants was 49 years old (range 34-68 
years). The original indication for HSCT was leukaemia in all patients; acute 
myeloid leukaemia in two participants, chronic lymphoid leukaemia in two 
participants, and acute lymphoblastic leukaemia in one participant. 
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Clinical Features 
The vision was normal for all patients at baseline and remained better than 0.2 
logMAR (6/9 Snellen equivalent) at all post-transplant visits. 
All patients, were asymptomatic of ocular disease at baseline and follow up 
visits, with an OSDI score of < 12 for all patients at all visits. 
Clinical Signs of dry eye 
The eyes of all participants were healthy at baseline, and none of the 5 patients 
developed significant signs or symptoms of ocular disease. 
Details of the clinical features are shown in Table 10. At baseline, one patient 
had evidence of corneal staining with a modified Oxford score of 19 there was 
no corneal staining at baseline in the remaining patients and at subsequent 
visits, no patients developed significant ocular surface staining. 
At baseline, 2 eyes of one patient had a Schirmer’s score of <= 10mm in 5 
mins; at all subsequent visits all eyes of all patients had a normal Schirmer’s 




 Baseline 1 Month 3 Months 6 Months 12 Months 
Normal 
Schirmer’s’ (≥ 
10mm in 5 mins) 
8/10 8/8 3/3 4/4 4/4 















OSDI (number of 
eyes) 




305.5 301.1 317.5 315.5 302.5 (n=4) 
Number 
<316mOsm/l 185 




3.7 2.75 2.5 1.75 2.375 
Table 10 Dry Eye Characteristics of the longitudinal cohort. 
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At baseline, unanaesthetised Schirmer’s score was normal (≥ 10mm in 5 mins) 
in 8/10 eyes and was normal in all subsequent visits for all eyes. 
There was no change in the position of Marx’s Line over the one-year period. 
The mean Yamaguchi score at baseline, 1 month, 3 months, 6 months, and 12 
months were 3.7, 2.25, 1.75 and 2.375 respectively. 
Resident Conjunctival Leukocyte Population 
In healthy volunteers, there were very few resident leukocytes in the conjunctiva 
(Figure 21), with the predominant cells being CD8+ lymphocytes as has been 
previously described.33,109  
Figure 21 Representative Flow Cytometry Data from the conjunctiva of a healthy volunteer after 
gating as previously described. A shows Neutrophils CD16+/CD11b+). B shows CD8+ and CD4+ 
lymphocytes. C shows macrophages (CD45+ and CD14+) cells, note this is subsequently 
backgated onto FS and SS to exclude lymphocytes (CD3+) cells which shared the same 
fluorochromes as CD14. 
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Reconstitution of Myeloid Derived Cells in the Blood and Conjunctiva 
Reconstitution of myeloid derived cells, in both the blood and the conjunctiva is 
shown in Figure 22. Before HSCT, at baseline, the numbers of myeloid derived 
cells in the blood and conjunctiva were not significantly different to those in 
healthy volunteers, with no significant difference in the number of monocytes, 
NK cells or neutrophils when compared to healthy volunteers. Following HSCT, 
at one month post-transplant, the numbers of monocytes, neutrophils and NK 
cells fall, in the blood, with significantly lower number of monocytes (p=0.0159), 
NK cells (p=0.0317) and a trend to reduced neutrophils (p=0.11) in the blood 
when compared to baseline. At 3 months, the numbers of these cells have 
returned to baseline, with no significant difference in the numbers of monocytes, 
neutrophils or NK cells; and there remains no significant difference in the 
numbers of myeloid derived cells at the 12-month time point. In the conjunctiva, 
however, there is no significant change in the numbers of macrophages, 
neutrophils or NK cells at one-month and there remains no difference at the 3-







Figure 22 Reconstitution of Myeloid Derived Cells in lysed blood and conjunctiva 
showing the median and interquartile range of cell numbers. A. Monocytes B. 
Neutrophils, and C NK cells. Note significant fall in the number of Monocytes and NK 
cells and a trend to reduced neutrophils whilst there is no significant change in the 
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Reconstitution of Lymphocytes in the Blood and Conjunctiva 
When compared to healthy volunteers, there was no significant difference in the 
number of CD4+, CD8+ or NKT cells in the blood or conjunctiva at baseline. 
Representative flow cytometry data of conjunctival lymphocytes at baseline, 1 
month and 6 months is shown in Figure 23 .  
 
Figure 23 Representative Flow cytometry plot of a single patient. A Peripheral 
blood. Demonstrating high levels of CD4 and CD8 cells at baseline, with a marked 
reduction in cell numbers at one month post-transplant, with cell numbers 
returning to normal at 6 month post-transplant. This picture is mirrored in the 
conjunctiva in B with almost complete depletion of CD4 and CD8 lymphocytes in 
the conjunctiva at 3 months post-transplant, and cell numbers returning to normal 


















The changes in the numbers of lymphoid cells in the both the blood and the 
conjunctiva following HSCT and in healthy volunteers is shown in Figure 24. 
Following conditioning and HSCT, there is a fall in the number of lymphocytes 
found in the blood, with significantly lower CD4+ cells (p=0.0195), CD8+ cells 
(p=0.0159) and NKT cells (p=0.0159) at one month compared to baseline. The 
number of CD4+ and CD8+ cells remains low at 3 months when compared to 
baseline (p=0.0357), but the number of NKT cells has returned to baseline. At 
six months, there is no significant difference in the number of CD4+ and CD8+ 
cells when compared to baseline, although there is a trend to reduced CD4+ 
cells (p=0.011).  
In contrast to conjunctival myeloid derived cells, there is a fall in the number of 
conjunctival lymphocytes after HSCT, with significantly fewer conjunctival CD4+ 
(p=0.0211) at 1 month, but not CD8+ or NKT cells. At the 3-month time-point, 
the number of conjunctival CD4+, CD8+ and NKT cells are significantly lower 
than at baseline (p=0.0029, p=0.0005 and p=0.0398 respectively).  
When the 12-month conjunctival leukocyte numbers are compared with healthy 
volunteers, we found significantly higher numbers of CD4+ lymphocytes 
(p=0.0263) but not CD8+ lymphocytes and this resulted in a significant change 






Figure 24 Reconstitution of Lymphoid Cells in lysed blood and conjunctiva 
showing the median and interquartile range of cell numbers. A. CD4+ 
Lymphocytes B. CD8+ lymphocytes, and C NKT cells. Note that there is a fall 
in the number of lymphocytes in the blood, but in contrast to the myeloid 
derived cells, there is a corresponding fall in the number of CD4+, CD8+ and 
NKT Lymphocytes. 
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In order to look at these lymphocyte populations in more detail, we then looked 
at the CD45RO marker, which is not expressed by naïve T-cells. Comparing the 
expression of CD45RO+ in CD4+ lymphocytes and CD8+ lymphocytes in 
patients undergoing HSCT and healthy volunteers. Figure 25 shows the median 
proportion of CD45RO+ CD4+ and CD45RO+CD8+ lymphocytes in the blood in 
patients before HSCT and in healthy volunteers. We found significantly higher 
percentage of CD4+CD45RO+ in pre-HSCT patients when compared to healthy 
volunteers. 
  
Figure 25 Comparison of the median and range of the  
ratio of blood CD4 and CD8 lymphocytes that express 
CD45RO in patients pre-HSCT and healthy volunteers. 
Note there are significantly more CD45RO+/CD4+ cells in 
the blood of patients before HSCT and healthy 
volunteers. 
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Figure 26 shows the median numbers of CD4+/CD45RO+ and CD8+/CD45RO+ 
cells in the conjunctiva in both post-HSCT patients and healthy volunteers. 
After HSCT, there is a significant increase in the percentage of 
CD4+/CD45RO+ cells (p=0.0095 and CD8+/CD45RO+ cells (p=0.0190). At 12 
months, the number of both CD4+/CD45RO+ and CD8+/CD45RO+ cells were 
no different to baseline (p=0.931 and 0.792 respectively). 
Figure 26 Median and range of the ratio of CD45RO+ and - lymphocytes in the 
conjunctiva A CD4+ cell and B CD8+ cells for healthy volunteers (blue) and post-




At baseline, almost all the conjunctival CD4+ and CD8+ cells express 
CD45RO+. Immediately following the transplant, the CD45RO percentage of 
CD4+CD45RO+ cells remains high, but starts to fall, with a higher percentage 
of both CD4+ and CD8+ not expressing CD45RO. The number of 
CD4+CD45RO+ cells was significantly lower at 12 months than at baseline 
(p=0.0133), there was a trend to a reduced number of CD8+CD45RO+ cells, 
but this did not reach statistical significance. 
Discussion 
 Lymphocyte Reconstitution 
As would be expected, following myeloablation, there is a rapid reduction in the 
number of both blood lymphocytes and resident conjunctival lymphocytes. As 
previously discussed, the T-Cells in the blood take many months to return to the 
pre-transplant numbers, and this was indeed the case in our cohort, with both 
CD4+and CD8+lymphocyte numbers falling in both the blood and the 
conjunctiva. In the conjunctiva, there is a fall in the T-cell numbers, with 
CD4+cells low at 1 month, and both CD4+and CD8+cells significantly low at 3 
months when compared to baseline. The reason that CD8+cells are not 
significantly lower at the 1-month time point in the conjunctiva could be that the 
alemtuzumab failed to deplete resident CD8+cells. In patients with Cutaneous T 
Cell Lymphomas, alemtuzumab is used to deplete the cancerous T-cells. It has 
been shown that resident TEM cells, both CD4+and CD8+(but not recirculating 
cells) can survive the alemtuzumab. 186 The majority of conjunctival CD8+cells 
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demonstrate mucosal homing markers and are likely to be tissue resident, until 
being lost from the conjunctival surface.99, however it is feasible that a smaller 
subset of conjunctival CD8+cells are able to survive alemtuzumab, and there is 
a marked trend for reduced CD8+cells post-transplant, suggesting that the 
majority of CD8+cells were depleted by the alemtuzumab.  
As discussed above, the reconstitution of T-cells follows a biphasic pattern, with 
initial expansion of donor-derived mature T-cells and subsequent thymic 
maturation and expansion of transplanted naïve T-cells. Before and 
immediately after conditioning and HSCT, the majority of T-cells in the 
conjunctiva are experienced, memory T-cells. In the first month following 
transplant, the majority of both CD4+and CD8+cells are CD45RO+ suggesting 
an effector memory phenotype. These cells likely represent the first ‘phase’ of 
reconstitution, the expansion of transplanted mature T-cells. At later time points 
the proportion of conjunctival, but not blood, CD45RO-lymphocytes increases. 
We propose that these cells represent the second ‘phase’ of constitution, 
expansion of naïve T-cells. Even in the absence of clinical disease or signs of 
inflammation, there is a significantly increased number of CD4+cells in the 
conjunctiva when post-HSCT patients, at the 12-month point, are compared to 
healthy volunteers. At this timepoint, there is a significantly reduced number of 
CD4+CD45RO+ cells, conjunctiva and the numbers of CD45RO+ cells in the 
blood is not significantly different to baseline; suggesting the increase is due to 
migration of naïve CD4+T-cells into the conjunctiva. Naïve T-cells circulate 
through secondary lymphoid organs and so their presence in the peripheral 
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tissue is unexpected. There are three possible reasons for this. Firstly, although 
the majority of CD4+cells pre-HSCT were CD45RO+; following transplant and 
reconstitution a higher proportion of conjunctival CD4+T-cells are now 
‘revertant’ (TEMRA) and fail to express CD45RO. Without knowing whether these 
cells express CCR7, it is not possible to say these cells are truly naïve. 
Secondly, it could be possible that there is sub-clinical inflammation in the 
conjunctiva. although the numbers of innate immune cells in the conjunctiva at 
12 months is no different in post-HSCT patients and healthy volunteers. Finally, 
it could be that there is recirculation or trafficking of naïve T-cells though the 
conjunctiva. The view that naïve T-cells are confined to secondary lymphoid 
tissues and do not enter peripheral tissue has been questioned187 and it has 
been shown in mouse models, that there is a small but significant number of 
naïve T-cells can be found in non-lymphoid tissue 188 and it has been shown 
that there are small numbers of naïve T-cells in the human conjunctiva 
especially in the context of dry eye disease.101 
Myeloid Derived Cell Reconstitution  
Whilst numbers of monocytes fall rapidly after conditioning, the numbers in the 
blood return to normal within 3 months. In contrast, in the conjunctiva, there is 
no significant change in the number of macrophages before or after 
conditioning and HSCT. Using a mouse model of HSCT, Kennedy et al189 found 
that macrophage reconstitution occurs at different rates in different tissues; 
splenic macrophages are 89% donor-derived at one month, whereas at two 
months, alveolar macrophages were only 61% donor derived. This is consistent 
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with our findings that post-transplant macrophage numbers are no different to 
baseline. Unfortunately, we were not able to differentiate between host and 
donor-derived cells. Haniffa et al190 examined pre and post-conditioning skin 
shave biopsies and found skin resident macrophages survived conditioning, but 
the number of dendritic cells falls. This means that we are not able to determine 
whether there are any changes in the macrophage populations over time, as 
any reconstitution changes might be masked by survival of the host-derived 
resident macrophages. 
Neutrophils also fall rapidly in the blood following conditioning, but the levels at 
1 month are not significantly lower than at baseline. Neutrophils are the first 
leukocytes to reconstitute returning to normal levels after 11-14 days. 22 and so 
it is likely that the reason is that neutrophils are have reconstituted by the 1 
month time-point. Similarly, there is no change in the numbers of neutrophils in 
the conjunctiva, again, this is likely because by the one month time point, they 
have already reconstituted. 
NK cells also reconstitute in the blood early on after conditioning following 
transplantation, and normal NK cell levels can be expected in the first month. 
191. Post-HSCT, donor NK cells play an important role in the GVT response and 
it has been demonstrated in vitro, that donor-derived NK cells can lyse tumour 
cells. 192 Furthermore, NK cells can inhibit T-cell activation and ameliorate 
GVHD. 193 In our patients, T-cell depletion was performed pre-HSCT, and 
different methods of T-cell depletion has been shown to affect the kinetics of NK 
85 
reconstitution.194, additionally systemic immunosuppression may affect NK 
reconstitution independently of T-cell depletion.195 Nevertheless, it is not clear 
why the numbers of NK cells in the blood is low in our patients at the one month 
timepoint.  
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Chapter 4 Cross-Sectional Cohort 
Patient Recruitment 
A cross-sectional cohort of patients was also recruited from the haematology 
clinics at the Centre for Clinical Haematology at the Queen Elizabeth hospital. 
Patients who had undergone HSCT were recruited, including patients with and 
without systemic or ocular GvHD. Patients were excluded if they had any history 
of ocular disease pre-dating HSCT. 
Patients were seen for a single visit, where clinical assessment and sampling 
were performed as previously discussed. 
Results 
A total of 29 patients were recruited. 11/29 (40%) of patients were female, the 
average age was 50 years old (range 21-66 years). The majority of patients 
were White (26/29) with the remaining patients Asian (3/29). The average time 
patients were seen post-HSCT was 235 days (range 94-876 days).Patient 
demographics and transplant conditioning regimen are shown in Table 11 The 




Age Average Age 50 
 Range 21-66 
Gender Female 11 
 Male 18 
Ethnicity White British 26 
 Asian Pakistani 1 
 Asian Bangladeshi 1 
 Asian Other 1 
Indication for Transplant Acute Myeloid Leukemia 12 (41%) 
 Acute Lymphoblastic Leukaemia 5 (17%) 
 MDS 3 (10%) 
 Chronic Lymphoid Leukaemia 2 (7%) 
 Anaplastic Anaemia 2 (7%) 
 Chronic Myeloid Leukaemia 1 (3%) 
 Follicular Lymphoma 1 (3%) 
 Hodgkin’s Lymphoma 1 (3%) 
 Non-Hodgkin’s Lymphoma 1 (3%) 
 Probable T-cell Prolymphocytic Leukaemia 1 (3%) 
Conditioning Fludarabine/Melphalan/Campath 19 
 Cyclophospamide/TBI 6 
 Cyclophospamide/TBI/Fludarabine 1 
 BEAM/Campath 1 
 Bisulphan/Cyclophosphamide 1 
 FLAMSA/Bu 1 
   
 Reduced Intensity 4 
Donor Sibling 15 
 Unrelated 14 
Transplant Source Peripheral Stem Cell 21 (70%) 
 Bone Marrow 7 (24%) 
 Cord Blood 1 (3%) 
Chronic GvHD Nil 7 
 Mild 10 
 Moderate 10 
 Severe 2 
Table 11 Cross-sectional cohort patient demographics, conditioning, and HSCT details. 
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Ocular GvHD and Dry Eye Disease 
To assess the patient’s symptoms of dry eye disease, the NIH ocular severity 
scale and the OSDI were used and the results are shown in Table 12. The 
weighted kappa when comparing the NIH severity scale and OSDI was 0.030 
indicating a poor relationship. 





OSDI (0-100) n=23 
Average (range) 18 (0-66) 
Nil (<12) 11 
Mild (12-22) 6 
Moderate (23-32) 3 
Severe (33-100) 3 
Table 12 NIH Ocular GvHD Severity Score and Dry Eye Symptom Score (OSDI) in Cross-
Sectional Cohort of post-HSCT patients. These two scores describe the symptoms of 
patients with dry eye related disease.  
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NIH New Onset KCS n=29 
Present 6 
Absent 23 
Unanaesthetised Schirmer’s Score 
 (Average of two eyes) 
n=29 
Average (range) 15  (0-36) 
Schimer’s <=5mm/5mins 6 
Schirmer’s 6-10mm/5mins 5 
Schirmer’s >10mm/5mins 18 
Tear Break Up Time  (TBUT) 
(Average of two eyes) 
n=27 
Average (range) 6 seconds (0-20) 
TBUT <10 23 
TBUT >=10 4 
Modified Oxford Corneal Grading 
Score (Average of two eyes) 
n=29 




(Average of two eyes) 
n=20 
Average (range) 303.5 (286-325) 
Osmolarity >316 16 
Osmolarity <=316 4 




The diagnosis and severity of ocular GvHD and /or dry eye disease were 
assessed with a number of methods; the NIH severity score, Schirmer’s score, 
TBUT, Modified Oxford scale of corneal staining and the tear film osmolarity. 
The numbers of patients fulfilling each clinical parameter are shown in Table 13. 
The proportion of patients reported as having ocular GvHD or dry eye disease 
using each test or grading criteria are shown for comparison in Figure 27.  
 
The International Consensus Group proposed diagnostic criteria for Ocular 
GvHD6 combines different clinical signs seen in ocular GvHD as well as the 
presence of GvHD in other organs, the results are shown in Table 14. The 
Figure 27 Proportions of patients post-HSCT showing evidence of ocular 
GVHD/dry eye disease with each clinical test or scoring criteria. 
91 
weighted Kappa comparing the NIH criteria and the proposed diagnostic criteria 
was 0.519 indicating the strength of agreement is ‘fair’. 
International Chronic (GvHD) Consensus 
 Group Diagnostic Criteria 
n=23 
Definite [ocular GvHD] 2 
Probable [ocular GvHD] 5 
None [ocular GvHD] 16 
Table 14 International Consensus Group, proposed diagnostic criteria for ocular GvHD. 
Cicatricial Lid Features 
Cicatricial changes to the lid margin were assessed, in 25/29 patients,  using 
Yamaguchi’s scale to describe a posterior migration of Marx’s line. 9  The 
average Yamaguchi score for right and left eyes was 3.2 (SD 2.4 right and 2.2 
left). There was a positive correlation between the time post-HSCT and the 
Yamaguchi scale (Pearson p=0.0494 r=0.3376) indicating that the further in 
time from transplant, the more posterior migration of the meibomian gland 
orifices (Figure 28). 
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The majority of eyes (43/58) did not show evidence of subconjunctival fibrosis 
using Robinson’s grading system; 12/58 eyes had Grade 1 fibrosis and 3/58 
eyes had Grade 2 fibrosis. There was a trend to increased Robinson’s Grade 
and the number of days post-transplant, but this did not reach statistical 
significance (p=0.0553 Kruskal-Wallis). 
Conjunctival Leukocyte Populations and Ocular GvHD 
Table 15 shows the median cell numbers and interquartile range for each cell 
type in all post-HSCT patients, post-HSCT patients with new onset KCS, post-
HSCT patients without new onset KCS, healthy volunteers and patient with 
Sjögren’s Syndrome. These data are graphically displayed in Figure 29 and 
Figure 30. Post-HSCT patients with new onset KCS were found to have 
significantly higher number of CD8+ cells (p=0.04), macrophages (p=0.0001) 
and neutrophils (p=0.035) when compared to post-HSCT patients without new 
onset KCS. The percentage of CD8+/CD45RO+ cells was not significantly 
Figure 28 Scatter plot of time post-HSCT in days and 
Yamaguchi scale (averaged right and left eye) 
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higher in patients with KCS and without KCS. There was no significant 
difference in the number of CD4+ cells, NKT cells or NK cells. 















CD4 54 (106)   56 (91) 54 (115) 4 (20) 235 (431) 
CD8  194 (488) 557 
(214)  
 84 (350) 137 (367) 201 (431) 
NKT 5 (7.5)   14 (30) 5 (8)  3(2) 11(16) 




12 (75) 49 (111) 
NK Cells 97 (108)   91 (96) 97 (97)  6 (20) 71 (295) 
Neutrophils  78 (381)  190 
(2420) 
46 (245)  7(59) 174 (456) 
Table 15 Median cell numbers and interquartile range for each conjunctival leukocyte 
population in all post-HSCT patients, post-HSCT patients with and without new onset 





Figure 29 Conjunctival CD4+, CD8+, Macrophages, and Neutrophils in all patients post-
HSCT, post-HSCT patients with new onset KCS, post-HSCT patients without new onset 
KCS, healthy volunteers and Sjögren’s patients. Note significantly increased CD8+, 
macrophages, and neutrophils in post-HSCT patients with new onset KCS, compared to 
those without; and increased numbers of macrophages in patients with post-HSCT new 




Post-HSCT new onset KCS and comparison with healthy volunteers and patients 
with Sjögren’s Syndrome 
Table 16 shows Mann-Whitney results comparing the conjunctival leukocyte 
populations in all patients post-HSCT (with and without new onset KCS) 
compared with both healthy volunteers and patients with Sjögren’s Syndrome. 
When compared to healthy volunteers, patients with post-HSCT new onset KCS 
have significantly increased numbers of all leukocytes except for NKT cells.  
Despite, being a similar form of dry eyes disease, in Sjögren’s syndrome there 
is increased numbers of macrophages in post-HSCT dry eye and the Aqueous 
Deficient Dry Eye Disease in Sjögren’s Syndrome.  Interestingly this difference 
was not limited to the post-HSCT patients with KCS; post-HSCT patients 
Figure 30 Conjunctival NK T-Cells and NK cells in all patients post-HSCT, post-HSCT 
patients with new onset KCS, post-HSCT patients without new onset KCS, healthy 
volunteers and Sjögren’s patients. 
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without dry eye had increased number of macrophages, when compared to 
both healthy volunteers and patients with Sjögren’s syndrome. 
When the two control groups were compared; we found a trend to increased 
numbers of CD4+cells in the eyes with Sjogren’s syndrome (p=0.06), and 








CD4+ NS (p=0.09) NS 
CD8+ NS NS 
NKT NS NS 
Macrophages p=0.047 p=0.0446 
NK p=0.0038 NS 
Neutrophils p=0.0079 NS 
Post-HSCT 
New Onset 
KCS (Dry Eyes) 
CD4+ p=0.0455 NS (p=0.10) 
CD8+ p=0.0260 NS (p=0.10) 
NKT NS NS 
Macrophages p=0.0022 p=0.023 
NK p=0.036 NS 





CD4+ NS  NS 
CD8+ NS NS 
NKT NS NS 
Macrophages p=0.0161 p=0.1471 
NK NS NS 
Neutrophils NS NS 
Table 16 Comparison of conjunctival leukocyte populations in patients post-HSCT with 
healthy volunteers and Sjogren's Syndrome patients.Shaded cells deomstrate where  the 
difference between the post-HSCT group and the control groups are signifcantly higher, 
or where there is a trend to higher numbers in the post-HSCT group. 
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Lysed Blood Leukocyte populations and Ocular GvHD 
We found no significant differences in the numbers of leukocytes in patients 
with new-onset KCS and those without.  (Appendix 3 Supplementary Data). 
Source of Donor Cells, ocular GvHD and Conjunctival Leukocyte Populations 
A total of 15/29 HSCT were from siblings, and 14/29 HSCT were from unrelated 
donors. The number of patients with KCS was 3/15 in the sibling group and 
3/14 in the unrelated group; chi-square testing did not show any significant 
difference between the two groups.  
Systemic GvHD and Conjunctival Leukocyte Populations 
Table 17 shows the NIH classification of chronic GvHD in the cross-sectional 
cohort of patients. 21/29 patients had some form of GvHD; using the NIH 
classification, 1/29 patient had severe GvHD, 10/29 had moderate GvHD, 10/29 
had mild GvHD and 8 patients had no evidence of GvHD. The breakdown of 













Table 17 The severity of GvHD in the Cross-Sectional Cohort of patients using the 
NIH Classification of GvHD severity. The majority of patients had either mild or 
moderate GvHD. 
 
Severity Score 0 1 2 3 
Performance Score 24 5 0 0 
Skin 19 6 3 1 
Mouth 24 0 2 3 
Eyes 17 9 2 1 
GI Tract 28 0 1 0 
Liver 28 0 1 0 
Lung 25 4 0 0 
Joint/Fascia 28 1 0 0 
Genital Tract 29 0 0 0 
Table 18 Further description of the NIH severity score for patients in the cross-
sectional cohort (total n=29), describing the NIH GvHD severity score (0-3) for each 
affected system. 
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In order to look into whether conjunctival leukocyte numbers were altered in 
patients with systemic GvHD, we excluded the ocular component from the 
global score and then divided the cohort into patients with and without any 
evidence of systemic cGvHD. There was no significant difference in the 
conjunctival leukocyte numbers when patients with systemic GvHD were 
compared with patients without systemic GvHD.  These data are shown in 
Figure 31.  
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Figure 31 Conjunctival Leukocytes populations in Healthy Volunteers, and 
post-HSCT patients with and without systemic GVHD (excluding ocular GVHD). 
Note there is no significant difference in the number of any of the populations 
examined in patients with systemic GVHD and without systemic GVHD. 
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Figure 32 shows the GvHD status of patients and whether they had evidence of 
GvHD in any other organ.  Whilst a higher percentage of patients (4/6 67%) with 
new onset KCS had evidence of GvHD in other organs, when compared to 
patients without new onset KCS (13/23 57%); this did not reach statistical 





Scoring Scales and Diagnostic Criteria 
The prevalence of ocular GvHD varied in our cohort depending on the 
diagnostic criteria used. With a prevalence varying from 6/29 (21%) using the 
NIH new-onset KCS criteria, to 12/29 (41%) using the NIH severity criteria and 
7/23 (30%) using the International consensus proposed diagnostic criteria.  
This variation in the number of patients highlights the difficulty in diagnosing 
ocular GvHD and the difficulty in grading the disease. The controversy 
Figure 32 Graph to show the numbers of patients with and without KCS 
and evidence of GVHD in any other organ. There was no signficant 
difference between the numbers of patients with KCS in patients with or 
without systemic GvHD. 
No KCS KCS 
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surrounding the different scoring systems for ocular GvHD are discussed in 
above. Despite being a very simple useable by any clinician, the NIH score has 
been shown to compare well with other dry eye scales. 62,63. Despite this, in our 
cohort, the Kappa score did not show a strong relationship between OSDI and 
the NIH score. This is surprising as the OSDI depends on patient reported 
symptoms and the NIH grading is heavily based on patient symptoms but could 
be explained by small numbers of patients with severe disease. In our cohort, 
the relationship between Schirmer’s score, a clinical sign, and the NIH grading 
score was ‘fair’. Schirmer’s score is an uncomfortable and time-consuming 
process; the NIH score, would therefore be a preferred option in haematology 
clinics to screen patients.  
A clinical grading scheme can have a number of purposes, for example, as a 
screening tool, to identify those patients who may need referral to a specialist, 
or as a severity tool to identify those patients who may need a change to 
treatment. The setting is also important to consider. A very detailed tool may be 
appropriate when administered for research purpose, but may not be useful in a 
busy clinical situation. Finally, it is important to include the patient’s own 
experience in assessing the severity of the condition, especially in a disease 
such as dry eye, where there is often a disparity between the severity of 
symptoms and signs. There is evidence that patients following HSCT are 
reticent to seek help for their eyes,127 and may suffer a reduced quality of life as 
a result,135  Use of the NIH severity scale allows the patient to express their 
symptoms, to allow the clinician to detect a change in the severity of the ocular 
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disease so as to direct ophthalmological referral, and finally use of the NIH 
ocular scale is an integral factor in assessing the overall effect of all GvHD 
status of the patient. Our data corroborates the published literature on the use 
of the NIH grading scheme in the haematology clinic. 
Although our data was limited, we did find a ‘moderate’ strength relationship 
between the NIH criteria and the proposed criteria, supporting the use of the 
new criteria in the clinical setting. It must be pointed out that, as it is more 
detailed, the consensus criteria would require a suitably trained and 
experienced examiner, and specialist equipment, namely a slit-lamp 
biomicroscope. This would make routine use in non-ophthalmology clinics more 
difficult and possibly not feasible. Nevertheless, this scale uses predominantly 
clinical signs, being a more detailed scale, the proposed International criteria is 
also capable of providing a numerical value, and this might provide a degree of 
granularity that would be more useful in a research setting. 
The proposed International consensus diagnostic criteria include whether there 
is evidence of systemic cGvHD (Table 4); two factors from our cohort would 
question this. Firstly, although more patients with new onset KCS had systemic 
cGvHD, this did not reach statistical significance. Secondly, we did not show 
any difference in the conjunctival leukocyte population in patients with and 
without systemic cGvHD. Finding a number of patients with dry eye disease 
without cGHVD  is not inconsistent with the literature, as although the majority 
of published cohorts show ocular GvHD in patients is more with systemic 
104 
cGvHD, ocular GvHD without systemic GvHD is far from uncommon with  
number of studies report ocular GvHD in the absence of systemic cGvHD. 
126,128-130,196 Use of this scale could potentially lead to underdiagnosis and the 
potential consequences of this to the patient should not be underestimated. 
127,128,135 Whilst there is evidence to suggest patients with systemic cGvHD may 
have more severe disease196 , due to the application to the proposed diagnostic 
criteria could lead to the situation whereby two patients with identical signs of 
ocular disease are classified differently, and treated differently. 
Cicatrisation and Ocular Surface Fibrosis following HSCT 
We found some evidence of increasing subconjunctival fibrosis in patients 
following HSCT, and this fibrosis was associated with time following 
transplantation. There was a trend to more subconjunctival fibrosis, using 
Robinson’s classification, in patients who were further from their HSCT. 
Yamaguichi’s score, describing the migration of Marx’s line, a sign of cicatricial 
changes, was significantly higher in patients who were longer from their 
transplant. As described above, fibrosis is a feature of lacrimal gland GvHD, but 
cicatricial conjunctival changes are common to a number of ocular surface 
disease, including pSS. 
Changes in the ocular surface leukocyte populations in patients with KCS post-
HSCT.  
Which leukocyte populations were raised, depends very much on which 
population was used a control group. We have shown in Chapter 2 that the 
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resident conjunctival lymphocyte population of patients post-HSCT is not the 
same as that in healthy volunteers with increased CD4+ lymphocytes and an 
increase in the number of naïve T-cells, even in the absence of clinical disease. 
This highlights the importance of choosing an appropriate control group. When 
compared to post-HSCT patients without KCS, there are significantly higher 
numbers of CD8+ cells, macrophages and neutrophils. A limitation of our 
method was that we were unable to ascertain the origin of conjunctival 
leukocytes. As discussed above, in an animal model of ocular GvHD, Herretes 
et al197  were able to demonstrate infiltrating T-cells were of donor origin.  
Lymphocytes 
CD4+cells 
T-Cells have been heavily implicated in both animal models and human dry eye 
disease198 and topical Ciclosporin, a T-cell suppressor, has been a mainstay of 
dry eye treatment for over a decade.  In our cohort of patients with pSS, the 
majority of infiltrating lymphocytes are CD4+ cells and this is consistent with the 
published literature on Sjögren’s syndrome.176 Whilst the difference did not 
reach statistical significance , there was a trend to higher numbers of CD4+ 
cells in pSS when compared to both healthy volunteers (p=0,06) and post-
HSCT with KCS (p=0.09). CD4+ cells have been heavily implicated in human 
dry eye disease176 and the desiccating stress model of dry eye disease, with 
adoptive transfer of CD4+cells into T-cell depleted mice ‘transferring’ dry eye 
disease.177 In our cohort of patients with GvHD related disease we found that 
106 
number of conjunctival CD+ T-cells were similar to those in patients without dry 
eye disease and this suggests that the inflammatory process on the ocular 
surface of patient with dry eye disease related to GvHD is a distinct process to 
that occurring as a result of the aqueous deficiency state found in Sjögren’s 
Syndrome. 
CD8+Cells 
In the healthy human conjunctiva, the majority of CD8+ cells are cytotoxic TEM.99 
CD8+ T-cells have been shown in the conjunctiva of patients with ocular GvHD, 
by a number of authors94,140-142 although using different methods, with some 
studies not employing double CD3+ and CD8+ staining and some using 
different control groups, such as healthy volunteers or autologous HSCT 
patients In contrast, it has been shown in other ocular surface inflammatory 
conditions that CD8+ T-cell numbers are reduced, for example ocular SJS199 
and ocular  MMP200. It is important to note that CD8+cells may play a variety of 
roles in mucosal surfaces; with different populations of CD8+lymphocytes 
serving distinct functions. For example, regulatory CD8+cells have been 
demonstrated in a mouse model of pSS to mitigate the effects of Th17 cells  in 
a mouse model of pSS201 and a desiccating stress model of dry eye disease.198    
CD8+T-cells are also seen in oral cGvHD, where infiltrating CD8+lymphocytes 
have been demonstrated to be cytotoxic TEM, and are closely associated with 
apoptotic keratinocytes.  79  In general, however , peripheral cGvHD is mediated 
by CD4+lymphocytes and other forms of GvHD are associated with a 
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predominant CD4+infiltrate; including intestinal GvHD91, pulmonary GvHD92  
and skin cGvHD. Nevertheless, γδ IEL CD8+cells have been shown in a mouse 
model of intestinal GvHD to be cytotoxic through a Fas-mediated pathway. It is 
likely that the CD8+cells we have demonstrated in the ocular surface may play 
a similar cytotoxic role. 
Macrophages 
In a murine experimental model of dry eye disease, macrophage numbers were 
shown to be unchanged, but the phenotype was different, with a higher 
proportion of M1 macrophages to animals without dry eye. 174. Nevertheless, a 
number of authors have demonstrated increased number of macrophages in 
dry eye disease.171 172 173  
Macrophages have also been implicated in other conjunctival inflammatory 
diseases such as Mooren’s ulcer202, vernal keratoconjunctivtis203,204 and in the 
Chinese hamster model of acanthamoeba keratitis, activation of macrophages 
has been shown to improve the disease.205  
We found significantly increased numbers of macrophages in the conjunctiva of 
patients with new onset KCS. Importantly, this was not only found when post-
HSCT patients were compared with healthy controls, but also when compared 
to patient with pSS. It is important to note the varied possible function of 
monocytes; for example, Extracorporal photopohoresis, a treatment for GvHD, 
has been shown to increase the number of myeloid derived suppressor cells 
(MDSC) furthermore these MDSCs show the ability to suppress T-cells.206 Little 
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is known about the possible roles of MDSC’s in the eye, but they have been 
shown to suppress T-cells in murine models of corneal transplants.207   
It has been shown in cutaneous GVHD that there are increased number of 
recipient derived macrophages in skin GvHD lesions.190 In a mouse model of 
allergic conjunctivitis, it has been suggested, that conjunctival macrophages act 
as APCs.208 Using a mouse model of ocular GvHD, Herretes et al reported 
increased macrophages in the conjunctiva5 and speculated that macrophage T-
cell interaction is critical to the process of ocular damage. Given our findings of 
increased macrophages, this would seem plausible, especially considering that 
in the pSS cohort, the macrophage numbers were significantly lower. 
Neutrophils 
An increased number of conjunctival neutrophils have been reported in a 
number of ocular surface inflammatory diseases, including dry eye disease209, 
infective conjunctivitis210, pseudomonas keratitis211, fungal keratitis212,  Stevens-
Johnson Syndrome199, ocular mucous membrane pemphigoid200, but also in 
animal models of corneal trauma213 and systemic diseases including cystic 
fibrosis214 and chronic smoking215. Neutrophils serve a number of 
immunological functions; in particular, as part of the innate immune system they 
play an important role the removal of pathogens though a number of 
mechanisms. One of these mechanisms, involves the secretion of extracellar 
DNA in the form of Neutrophil Extracellular Traps (NET). 216Tibrewal et al217 
examined tear fluid from a mixed cohort of patient with dry eye disease, 
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including patients with ocular GvHD. They found increased levels of extracellar 
DNA in the tear film of patients with dry eye, and the highest levels found in the 
ocular GvHD cohort. Neutrophil function is not restricted to killing of pathogens 
however, (for a review see Scapini et al218) and there is significant cross-talk 
between neutrophils and other immune cells including lymphocytes. This 
relationship is predominantly a suppressive response219, but there is evidence 
that neutrophils can cross-present present antigens to CD8+ cells220 and that 
through NETs, neutrophils can reduce the activation threshold of resting T-
cells.221 
Neutrophils are found in acute cutaneous GvHD69 and liver GvHD222 In a 
murine model of intestinal GvHD, Schwab et el reported on the role of 
neutrophils in intestinal GvHD.42 They found that neutrophils did not accumulate 
in germ-free conditions, GvHD severity was reduced with depletion of 
neutrophils and in TLR deficient neutrophils. The ocular surface microbiome223 
may play a similar role in ocular GvHD. 
In conclusion, in ocular GvHD, there is an inflammatory infiltrate composed of 
CD8, macrophages and neutrophils that is not present in patients post-HSCT 
who do not have ocular GvHD. Furthermore, this inflammation is distinct from 
the inflammation in aqueous deficient dry eye disease, suggesting that the 
inflammation is due to GvHD, rather than desiccating stress.  
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Natural Killer Cells 
We found no significant difference in the number of NK cells in the conjunctiva 
of patients with new onset KCS, and those post-HSCT patients without KCS. 
When compared with healthy volunteers, however, there was an increased 
number of NK cells in post-HSCT KCS patients and all post-HSCT patients 
regardless of KCS. NK cells have a varied role in GvHD.224, with donor derived 
NK cells encourage engraftment and prevent GvHD through suppression of 
donor derived T-cells. 193.  
We also found an increased number of NK cells in the eyes of patient with pSS 
when compared to healthy volunteers, suggesting that the increased number of 
NK cells is due to aqueous deficiency rather than a GvHD response. Indeed NK 
cells have been implicated in the induction of dry eye disease, and the dry eye 
disease can be ameliorated in NK deficient mice. 175 
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Chapter 5 Summary of Thesis and Conclusions 
Clinical Grading of Ocular GVHD 
Clinical scoring and diagnostic criteria of ocular GVHD is complicated by the 
fact there are a number of options. This complexity is bought about by the fact 
that different systems are needed in different situations for different purposes. A 
haematologist in clinic will need a quick, easy to use system that will allow the 
haematologist to determine whether the patient has symptoms that warrant 
referral to the ophthalmologist, as well as to allow them to fit the ocular 
symptoms into the context of the patient’s overall clinical picture, and construct 
a global view of a patient’s GvHD. To this end, in the most recent 2015 NIH 
Consensus guidelines for clinical trials60, the need for Schirmer’s Score has 
been removed. For the ophthalmologist, more detailed systems may be use, so 
as to identify those patients in whom the disease is more aggressive and in 
whom, there is the risk of sight threatening disease. Finally any scoring system 
needs to be appropriate for the use of research, both clinical and basic science, 
to allow patients to be arranged into cohorts, but also to be stratified according 
to disease severity. Whilst we have demonstrated the pathophysiology is 
different to other autoimmune forms of dry eye disease, such as Sjögren’s 
Syndrome, the clinical picture of ocular GVHD can be described with existing 
tools for dry eye disease, such as the DEWS II severity scale or the Ocular 
Staining Score225. Indeed, ophthalmologists may be familiar with their use in 
clinical practise and they have been validated in other ocular surface disease 
112 
such as Sjögren’s syndrome226. In an effort to provide the ophthalmologist with 
a diagnostic tool, the International Consensus ocular GVHD diagnostic criteria 
were published. 6 and recently validated 65 against a Best Practise Score and, 
importantly, the 2015 NIH consensus for clinical trials, thus allowing comparison 
between the haematology and ophthalmology clinic.  The relevance of 
diagnostic criteria to basic science research is questionable, as the likelihood of 
a diagnosis may not relate to the severity of a pathological process. Our data 
would support this, as we did not find the same increased numbers of CD8+and 
monocytes as we did find when using other methods, such as the Schirmer’s 
score and the new onset KCS criteria. Since we have shown that the ocular 
surface lymphocyte populations are different in post-HSCT patients regardless 
of ocular disease, and that the presence of systemic GVHD does not influence 
the ocular surface leukocyte populations: it could be argued, that the presence 
or absence of systemic GVHD has little or no impact on the eyes. If this is 
indeed the case, I would question whether, for basic science trials, the ‘second 
step’ where the clinical score is converted into diagnostic score (nil, probable, 
possible) should be omitted and analysis using the composite score only. 
Conjunctival Immune Populations Post-HSCT 
Peripheral tissue reconstitution has been poorly studied in the human, due to 
the difficulty in obtaining tissue biopsies which require invasive procedures. 
Most of the published literature comes from animal studies, with models of 
HSCT. We were able to study peripheral tissue reconstitution longitudinally in 
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representative human patients. After conditioning lymphocyte cell numbers fall, 
as they do in the blood. Some, possibly tissue resident, CD8+cells survive 
conditioning, but at the three-month time-point, CD8+cell numbers fall to 
become significantly lower than pre-transplant levels. This suggested that the 
lifespan of resident CD8+cells in the conjunctiva is less than 3 months.  
Compared to healthy volunteers, there are significantly higher numbers of 
CD4+lymphocytes in the conjunctiva at 12 months. This is not accompanied by 
an increase in the number of innate cells, such as macrophages or neutrophils. 
This presence of increased lymphocytes in the conjunctiva in the absence of 
ocular disease has been described before140 and in our cross-sectional cohort, 
we found increased CD4+in all patients post-HSCT when compared to healthy 
volunteers. The question remains, why these CD4+cells are entering the tissue 
from the circulation, even in the absence of clinical disease, indeed, we did not 
demonstrate an increased number of CD4+cells in the conjunctiva, when we 
compared post-HSCT patients with and without KCS. This CD4+may represent 
a subclinical inflammatory infiltrate, or that with an abnormally high proportion of 
naïve T-cells in the circulation, there is increased trafficking of naïve T-cells into 
the tissue. 
Nevertheless, we have shown the resident ocular surface CD8+ population is 
resistant to conditioning and T-cell ablation, but these cells are not detected at 
the 3-month time point, suggesting their lifespan is less than 3 months. We 
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have also found that reconstitution of the ocular surface is abnormal, with an 
increase in conjunctival CD4+cells when compared to heathy volunteers. 
Ocular GVHD Pathophysiology 
For ocular surface GVHD to be occurring, there needs to be immune mediated 
inflammation against the host, caused by transplanted donor cells or their 
progeny. GVHD has been shown to cause lacrimal gland inflammation, fibrosis 
and destruction. 3,4This causes aqueous deficiency, dry eye disease and the 
subsequent immune mediated ocular surface damage. This immune process 
has been extensively studied.198,227. The question remains as to whether the 
clinical picture of ocular surface inflammation we see in ocular GVHD is a result 
of the dry eye related inflammation caused by lacrimal gland destruction, or 
whether there is, superimposed on this inflammation, a true GVHD response. 
It has been long established that there is a lymphocytic infiltrate in the 
conjunctiva of patients with ocular GVHD8; and we were able to demonstrate 
the presence of CD8+lymphocytes in the conjunctiva of  patients as well as 
macrophages, and neutrophils. The literature, however, is unclear as to the 
phenotype of these lymphocytes; Rojas et al140 did not find increased 
CD8+cells, but Tatematsu94 and Auw-Haedrich 141 identified CD8+cells, but did 
not provide statistical analysis; whereas Eberwein et al142 did analyse numbers, 
but these failed to reach significance. In contrast, in a mouse model of ocular 
GVHD, found both donor derived CD4+and CD8+cells in the ocular surface of 
mice with ocular GVHD. This situation is further complicated by the fact that 
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CD8+cells are commonly found in the ocular surface109 and the control group 
chosen, with some authors using patients undergoing autologous HSCT, others 
using patients post-allogenic HSCT without ocular GVHD and others using 
healthy volunteers. In dry eye disease, the literature does not demonstrate a 
CD8+infiltrate, but CD4+(including Th17) cells are heavily implicated, both in 
animal models of dry eye disease, and Sjögren’s syndrome171,176 contrasting 
the immune process in GVHD and dry eye disease. CD8+cells are also found in 
other body sites with GVHD, notably the oral mucosa79, the minor salivary 
glands80, and in cutaneous GVHD71. In other sites, CD4+cells are more 
apparent such as the gastrointestinal tract,91 and the lungs. 92 Whilst we were 
unable to further phenotype the CD8+cells; it has been demonstrated that 
conjunctival CD8+cells are cytotoxic. 99 and so seems most likely that we are 
observing effector cytotoxic CD8 cells.  
The presence of macrophages in patients with KCS post-HSCT raises the 
question of whether there is antigen presentation on the ocular surface. 
Macrophages have been demonstrated to activate naïve CD8+ cells in vitro 228, 
furthermore in a humanised mice suffering from GvHD following immunisation 
with the pp65 viral antigen, it was found that there was interaction of naïve 
CD4+cells and surrounding clusters of macrophages in cutaneous GVHD-like 
lesions. 229. We also found evidence of naïve T-cells (CD4+CD45RO-) cells in 
the conjunctiva of patients post-HSCT. We did not, however, demonstrate 
increased number of macrophages in those patients we demonstrated 
increased numbers of CD4+CD45RO- cells and so local antigen presentation 
116 
seems unlikely. T-helper cells have been shown to interact with macrophages to 
induce antimicrobial action114, but in the absence of increased CD4+cells, it 
seems more likely that the macrophages are acting without assistance from T-
helper cells through innate pathways. Increased macrophage numbers have 
been found in dry eye disease171 172 173 although not all studies have found 
macrophages in the mouse model of dry eye disease174 and we did not find 
them in our disease cohort of patients with pSS. Nevertheless, macrophages 
have also been identified in the mouse model of ocular GVHD5 and T-cell 
macrophage interactions may well be very important in the disease. 
The inflammatory infiltrate in ocular GVHD is distinct to that found in dry eye 
disease and primary Sjogren’s syndrome, with a predominance of CD8+ cells 
and macrophage infiltration; indicating that there is a distinct inflammatory 
process occurring on the ocular surface in ocular GVHD. 
Suggestions for Future Work 
We have shown that the ocular surface lymphocyte populations post-HSCT are 
significantly different to those in healthy volunteers. In addition, even in patients 
without KCS, there were increased macrophages when compared to healthy 
volunteers. This highlights the importance of choosing an appropriate control 
group and an appropriate the time-point at which patients are seen.  We would 
also suggest that both healthy volunteers and post-HSCT without ocular 
disease are compared. 
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In our cross-sectional cohort, we found increased numbers of macrophages and 
CD8+cells are found in the conjunctiva of patients with new onset KCS. As 
discussed above, there is considerable difficulty in determining the best system 
to assess the presence/absence of ocular GVHD, as well as the severity of the 
disease. We were unable to validate the International ocular GVHD Consensus 
diagnostic criteria on our cohort, as low numbers and unavailable data. Further 
larger studies may help to validate, or invalidate the International Consensus 
diagnostic criteria and whether or not further criteria could be added to improve 
this system. 
One of the limitations of our current study, is that we were unable to detect the 
origin of the cells that we had found, and so we are unable to tell whether cells 
were donor or host derived. In most cases it would be difficult to assess the 
origin of cells, but for patients where there is a sex-mismatched transplant, it 
would be possible to identify the presence or absence of a Y chromosome 
using in-situ hybridisation. If, for instance, the raised CD8+T-cells in the 
conjunctiva were donor derived, perhaps more intensive forms of pre-transplant 
T-cell depletion might help prevent the ocular disease. We were also limited by 
the number of surface markers we were able to investigate with flow cytometry. 
Further studies might be able to phenotype the appropriate cell populations in 
more detail. In the longitudinal cohort, the increased number of CD4+CD45RO+ 
cells would be interesting to further phenotype; CCR7 would help us to identify 
whether these were revertant TEMRA cells or naïve T-cells. Further phenotyping 
of these CD4+ cells could be performed using cell stimulation and cytokine 
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assays, or analysis of tear cytokine levels in post-HSCT patients with no ocular 
disease. Tetramer staining might also be used to identify whether these cells 
recognise viral epitopes, or are indeed specific for host tissue. Given the 
predominance of Th17 in the animal models of dry eye disease, it would help to 
further differentiate the ocular surface inflammation in ocular GvHD from dry 
eye disease by looking for markers for these cells. 
Clinical Applications/Translation 
We have demonstrated that OSIC and flow cytometry is a practical, non-
invasive investigation that enables us to observe reconstitution in a peripheral 
tissue. Monitoring peripheral tissues may help us to understand the kinetics of 
peripheral reconstitution, perhaps allowing modifications to transplant protocols 
to improve outcomes for patients. Furthermore, we have also demonstrated 
changes in a peripheral tissue that are specific to GvHD. This technique 
provides the opportunity to monitor GvHD in a peripheral tissue, as well as an 
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Table 19 Median cell numbers and interquartile range for each leukocyte population in 
lysed blood in all post-HSCT patients, post-HSCT patients with and without new onset 
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